AN ANALYSIS OF CRO SELECTION PROCESS &RISK ASSESSMENT FOR ASTRAZENECA GENERIC DRUG DEVELOPMENT PROJECT IN CHINA by shetty, shraddha
shetty, shraddha (2012) AN ANALYSIS OF CRO 
SELECTION PROCESS &RISK ASSESSMENT FOR 
ASTRAZENECA GENERIC DRUG DEVELOPMENT 
PROJECT IN CHINA. [Dissertation (University of 
Nottingham only)] (Unpublished) 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/26033/2/Final_MBA_REPORT.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Shraddha Shetty Page 1 
 
 
 
 
 
 
 
 
 
 
 
AN ANALYSIS OF CRO SELECTION PROCESS &RISK 
ASSESSMENT FOR ASTRAZENECA GENERIC DRUG 
DEVELOPMENT PROJECT IN CHINA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUBMITTED BY, 
SHRADDHA SHETTY 
 
 
 
 
MBA 2012 
NOTTINGHAM UNIVERSITY BUSINESS SCHOOL 
Shraddha Shetty Page 2 
 
 
 
 
ACKNOWLEDGEMENT 
 
 
 
I would like to offer my deepest gratitude to my supervisor Professor Kulwant Pawar for giving 
me the opportunity to do this dissertation .His constant support and advice  was a source of 
inspiration for me to carry out this work. 
I would like to thank Mr. Dachen Cheng, Sr .Manager Sourcing, R&D at AstraZeneca for   
motivating me to do this research work. 
I am ever grateful to Miss Hai Hong Zhu, Sourcing Project Manager for being a wonderful 
mentor and for providing me with knowledge and information that I required to carry out this 
work. 
 I would like to thank Sarah Yan for her constant guidance. 
The Whole team of AstraZeneca China has been very kind to me and I cannot thank them 
enough 
I wholeheartedly thank Saurabh for always being there whenever I needed any help with my 
research work 
 
I would like to thank my professors in the University for their Guidance 
 
I would like to thank my friends Sandesh, Bhavana Payal, ,Kritika for their constant support. 
 
More importantly I would like to thank my parents for their love and constant prayers. I owe 
my happiness to them 
 
Shraddha Shetty Page 3 
 
ABSTRACT 
 
The current challenging situation  in the pharmaceutical  industry has caused has many big 
pharmaceutical companies  to move towards Generic drugs .As the markets in the western 
countries are nearing saturation emerging nations like India and China are attractive 
destinations for Pharma companies. 
The on-going healthcare reforms, rising economy, untapped rural market, improved 
infrastructure & population pool in China gives tremendous opportunities for pharmaceutical 
companies to grow their business. 
AstraZeneca, a leading global player in the Branded drugs recognizes the huge potential of the 
China Generic drugs Market. AstraZeneca aims to enter this market by producing high quality-
low cost generic drugs to the China broad market, but since it is new to the field of generics it 
has chosen for the CRO to play a major role in the development and registration of these drugs. 
 
This research work explores the various aspects of the AstraZeneca Generic drug development 
project (self-development project) highlighting   key areas like CRO selection process, project 
risk assessment & finally analysis of the AstraZeneca Generics drug Business model. 
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 CHAPTER 1 
 
INTRODUCTION 
 
1.1. Background 
 
The pharmaceutical industry after having witnessed years of steady and predictable growth is 
now entering a stochastic period. The recent  economic downturn, patents expiries ,  shrinking 
number of molecules in the company pipeline, increased price cuts by government, high  cost of 
R&D ,Intense generic competition and market saturation in developed countries  have caused a 
turmoil  in the pharmaceutical Industry. Apart from a few companies that have chosen to 
remain focused in branded pharmaceuticals most others have expanded into sectors such as 
diagnostics, consumer health, generic drugs, biosimilars, nutrition, and wellness. 
The large multinational companies are beginning to explore the untapped potential of 
emerging economies, like India and China. 
The Chinese pharmaceutical market is currently valued at $42 billion, with generics being 
responsible for a significant share of 63 per cent. The Chinese generics market is expected to 
reach $35 billion by 2015, thus making the future of generics drugs extremely promising. 
Moreover a major portion of China market is untapped (especially rural areas). In 2009 china 
launched an aggressive healthcare reform plan that intends to bring all its citizens under basic 
medical coverage, modernize its health infrastructure and improve grassroots healthcare 
delivery. 
This scenario indicates opportunity for a major pharmaceutical player like AstraZeneca who has 
been laying deep and broad roots in China for many years.AZ is presently looking to exploit the 
potential of the untapped China market by providing high quality generic drugs at a low cost and 
calls it the AZ China Broad Market project (AZ CBM).The broad Market project has several 
aspects and the Self-Development project is the one that presently holds vital importance to AZ. 
This is the main area of research in this report. 
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The scope of the Self-Development project is to select the suitable CRO to develop 15 OSD and 
prepare dossier for Regulatory approval. 
1.2. Research Objectives 
 
Primary Objectives 
 To understand and assess the current environment in China for generic product 
development and registration. 
 
 To Examine the CRO evaluation and selection process of the AZ Self-Development 
project and evaluate the capabilities of the ƐŚŽƌƚůŝƐƚĞĚZK ?Ɛ ? 
 
  Risk assessment of the project, including Supplier risk, molecule risk and overall 
project risk. 
Secondary Objectives 
 Highlight Generic Business Model of Big Pharmaceutical companies 
 Compare & Contrast AZ business model with others 
 
1.3. Dissertation Structure 
 
The dissertation consists of seven main chapters with supporting appendices at the end. 
Chapter 2 is literature review which discusses a wide array of literature on the topic of Supplier 
evaluation and selection processes .Supplier evaluation and selection is given high emphasis as 
CRO plays a vital role in the execution of the AZ Self-development project. Further literature on 
Risk Management is reviewed understand the various approaches and techniques used to 
evaluate risks in this project. The theories mentioned in the literature review will be referred to 
in the discussion section. 
Chapter 3 demonstrates the Research Methodology used to collect and analyse data to conduct 
this study. Chapter 4 is Current Scenario where in highlights of the on-going situation in the 
pharmaceutical industry and the shift towards generic drugs is discussed. A PESTEL analysis is 
carried out to capture the China Wmacro environment for the development and registration of 
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Generic drugs. This chapter introduces the AZ Self-Development project and maps the key 
processes and strategic issues in the project. 
Chapter 5 is the Data analysis Section, which will be divided into three parts; CRO selection and 
Evaluation, Molecule Assessment & Project risk assessment all of which are very important 
aspects of the Self-Development project. 
The first section will carry out a detailed study of the CRO selection process. Then the Strengths 
ĂŶĚ ǁĞĂŬŶĞƐƐ ŽĨ ƚŚĞ ĨŝŶĂů  ? ZK ?Ɛ ĂŶĚ ƚŚĞ ŽƉƉŽƌƚƵŶŝƚŝĞƐ ĂŶĚ ƚŚƌĞĂƚ they pose to AZ will be 
ĂŶĂůǇƐĞĚ ?ƐƵƉƉůŝĞƌƌŝƐŬĂƐƐĞƐƐŵĞŶƚǁŝůůƚŚĞŶďĞƉĞƌĨŽƌŵĞĚĨŽƌƚŚĞƐŚŽƌƚůŝƐƚĞĚZK ?Ɛ  ?dŚĞ ?nd 
section; Molecule assessment will scan the molecule selection process for the pilot project. The 
3rd section; Project risk assessment will map the various project risks, evaluate their likelihood 
and impact of occurrence and then devise the response plan. 
Chapter 6 contains discussion on empirical evidence as against the literature review on areas 
such as Supplier selection, supply strategy , risk assessment and other important aspects of the 
Self-Development project. Then Generic Business Model of Big Pharmaceutical companies is 
discussed, ĐŽŵƉĂƌĞĚ ĂŶĚ ĐŽŶƚƌĂƐƚĞĚ ĂŐĂŝŶƐƚ  ?Ɛ ďƵƐŝŶĞƐƐ ŵŽĚĞů ? &ŝŶĂůůǇ ? ŚĂƉƚĞƌ  ? ŝƐ
conclusion and recommendation section, which summarizes the study and makes future 
recommendations. 
 
 
 
 
 
 
 
 
 
 
  
Shraddha Shetty Page 10 
 
CHAPTER 2 
 LITERATURE REVIEW 
 
Literature review is integral part of entire research process and makes valuable contribution to 
every operational step. 
Its purpose is to: 
a. Bring clarity and focus to the research topic; 
b. Improve methodology 
c. Broaden knowledge in research area 
d. Contextualise the findings 
 
CRO plays a very significant role in the execution of Astrazeneca Self-Development project and 
therefore AZ has laid very high emphasis on the CRO selection process.Thus a major aspect of  
literature review is carried out on Supplier evaluation and selection process and techniques to 
gain more knowledge in this area and critically assess the evaluation process of AZ following 
chapters. 
AZ BM Self-Development project  consists of several risk factors. Assessing various project risks 
is vital to the smooth operation of a project.AZ uses detailed risk management techniques to 
assess and evaluate various risks.Thus the second part of of literature review is carried on Risk 
Management  
 
 
2.1. Supplier Selection and Evaluation 
 
 
 To thrive and sustain in current global market characterized by globalization, rising customer 
expectations, expanding regulatory compliance, global economic catastrophe, and intense 
competitive pressure selection and maintenance of core suppliers is a must( Enyinda et 
al,2010) .Suppliers have been acknowledged as the best intangible assets of any business 
organization (Muralidharan et al. 2002).  “Previouslypurchasing was not part of the executive 
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radar screen. But now due to the emphasis on core capabilities and competencies which often 
results in the outsourcing of major requirements now make supplier evaluation and selection a 
critical organizational process´(Trent,R;2007 ). In  today's  competitive  environment  it  is  
impossible  to  successfully produce low  cost,  high  quality  products  without  efficient 
suppliers.  Thus  one  of  the  most  important purchasing  decisions  is  the  selection  and  
maintenance  of  a  competent  group  of suppliers(Weber et al,1991) 
 
Supplier selection methods are the models or approaches used to conduct the selection 
process.  The methods chosen are extremely important to the overall selection process and can 
have a significant influence on the selection results. A number of well-known selection methods 
have been developed and classified by various scholars over the years. Certain methods have 
been popular selection choices for years, while other methods have only been developed 
recently. (Tahriri.,et al 2007) .Experts opine  that no best way exists to evaluate and select 
suppliers. “Usually when a company sets out to develop or choose a supplier selection method, 
the result is a combination of several different methods with different strengths suited to meet 
ƚŚĞĐŽŵƉĂŶǇ ?ƐƐƉĞĐŝĨŝĐƐĞůĞĐƚŝŽŶŶĞĞĚƐ ?. (Tahriri.,et al 2007).Supplier selection research can be 
categorized as either descriptive, describing actual practice, or prescriptive, demonstrating how 
suppliers should be selected given a set of selection criteria (Ellram 1990).  “Descriptive studies 
have addressed a wide array of issues. Early studies focused on identifying the criteria used by 
buyers to select suppliers. These have been extended to identify supplier selection under 
specific buying conditions; for example, strategic buyer supplier partnerships, single versus 
multiple sourcing, routine versus non routine purchases and direct versus indirect materials. 
Prescriptive research in supplier selection has used a variety of methodologies including 
mathematical programming, weighted average methods payoff matrices and the analytic 
hierarchy process ?(Kannan.v et al 2002) 
 
Recently, De Boer et al. (2001) stated that a supplier selection problem typically consists of four 
stages: 
 (I) Problem definition 
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(ii) Formulation of criteria 
(iii) Qualification of suitable supplier (or pre-qualification)  
(iv)  Final selection 
An effective supplier survey should have definitive features such as comprehensiveness, 
objectiveness, reliability & flexibility. 
 
 According to Trent,R;(2007) supplier selection process generally follow a logical flow starting 
from identifying that a selection need exists to confirming agreement with the selected supplier  
A summary of stepwise supplier selection processes is presented below. 
 
Figure 1:Supplier Selection Process 
 
 (Source: Robert Trent, 2007) 
 
 
Shraddha Shetty Page 13 
 
2.1.1. Recognize supplier selection need 
 
Some of the ways through which supply managers recognize a supplier selection need exists 
are: 
 Through involvement in new product development teams 
 From internal customer requests 
 During supply base reduction or optimization 
 Due to  expiring of  contracts 
 During strategy development 
 During Outsourcing 
 During geographic or capital expansion (Trent,R,2007) 
 
 
2.1.2. Identify supplier requirements/criteria 
 
Supplier selection decisions are complex because various criteria must be considered in the 
decision-making process (Choy et al., 2002). 
In one of the pioneer works on supplier selection, ‘ Dickson ? recognized 23 criteria used for 
selecting a supplier. He indicated that quality, delivery, performance history, and warranty 
policies are the most important criteria in supplier selection process. (Thanaraksakul,W; et al 
2009).  ‘ĞŵƉƐĞǇ ?identified quality, delivery capability, and teĐŚŶŝĐĂůĐĂƉĂďŝůŝƚǇĂƐǀŝƚĂůĐƌŝƚĞƌŝĂ ?Ɛ 
in supplier selectionWeber et al., (1991).According to Weber et al., (1991) quality was 
considered to be the most important selection criterion. This was followed by delivery and 
cost.Ellram (1990) emphasized that organizations should not limit supplier selection decisions 
on the traditional price and quality criteria but also on long term and qualitative aspects such as 
strategic match and assessment of future manufacturing capabilities.While the approaches 
used o manage suppliers vary from firm to firm, certain trends can however be observed. 
YƵĂŶƚŝĨŝĂďůĞŽƌ “ŚĂƌĚ ?criteria such as price, delivery, quality, and service are consistently used 
for supplier selection and assessment.  “^ŽĨƚ ? ? ĚŝĨĨŝĐƵůƚ ƚŽmeasure elements such as 
management compatibility and strategic direction of the supplier has also been shown to be 
important, predominantly in the context of strategic buyer-supplier partnerships 
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(Ellram1990).In the current global and open innovation economy where concurrent product 
and supplier development are very important, strategic supplier selection and evaluation 
decisions must not be merely based on traditional selection criteria, like cost, quality and 
delivery; many other criteria should be considered with the target of developing a strong long-
term supplier relationship such as quality management practices, management practices, 
financial stability, technology and innovativeness level, suppliers attitude, suppliers co-design 
capabilities, and cost reduction abilities (Araz et al.,2007). 
 
Today, in many industries ,firms give suppliers increasing responsibilities pertaining to product 
design, development and engineering (Wynstra et al., 2001).Several researches have pointed 
out the benefits of including suppliers at the product/process design and development stages 
such as fast project development times, lesser development and product cost, development of 
alternative conceptual solutions, selection of the ďĞƐƚ ĞƋƵŝƉŵĞŶƚ ?Ɛ and technologies 
,improvedlevel of motivation of suppliers, increased supplier devised innovation and enhanced 
product quality. Therefore, design teams should select the suppliers from the perspective of 
new product development, design, manufacturing processes and manufacturing capability 
.Thus the supplier selection decision needs to incorporate design criteria into the assessment 
process. 
(Monczka et al. 1994;Burt and Soukup 1985;Araz et al.,2007). 
 
A research conducted by Vijay R. Kannan &Keah Choon Tan identifies relationships between 
criteria and a buying Ĩŝƌŵ ?ƐďƵƐŝŶĞƐƐƉĞƌĨŽƌŵĂŶĐĞ ?ZĞƐƵůƚƐ ŝŶĚŝĐĂƚĞ ƚŚĂƚ soft, non-quantifiable 
selection criteria such as a ƐƵƉƉůŝĞƌ ?Ɛstrategic commitment to a buyer has a greater effect on 
performance than hard, quantifiable criteria such as supplier capability, but still are considered 
to be less important. Not only ĚŽĞƐƚŚĞ “ƐŽĨƚĐƌŝƚĞƌŝĂ ? directly impact performance; it can also 
have an indirect impact. For example, it is simpler to address supplier delivery and quality 
problems if there is a relationship between buyer and supplier, and if there are shared 
expectations and objectives. This, nevertheless, requires that firms develop relationships with 
suppliers that are willing to develop closer ties, are ready to share confidential information, and 
are dedicated ƚŽ ƐĞƌǀŝŶŐ ƚŚĞ ďƵǇĞƌ ?Ɛ long-term needs. The study also underpins the need to 
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view suppliers as extensions of the buying firm itself and not as independent bodies that are 
dealt with at Ăƌŵ ?ƐůĞŶŐƚŚ. 
 
According to a study conducted by Thanaraksakul, W; et al (2009) in developing countries, it is 
ŶĞĐĞƐƐĂƌǇƚŽĨŽĐƵƐŽŶƉƌŽĚƵĐƚƌĞůŝĂďŝůŝƚǇĂŶĚƚŚĞƐƵƉƉůŝĞƌ ?ƐĐĂƉĂĐŝƚǇŝŶďŽƚŚƚĞĐŚŶŝĐĂůĂŶĚ
production.  
 
In a research conducted on a generic pharmaceutical firm by using AHP it was found that the 
regulatory compliance selection criterion is most favored when selecting suppliers, this was 
followed by quality, risk, cost, supplier profile, and service ( Enyinda et al 2010 ) 
 
Regulatory Compliance: Pharmaceutical firms are required to update their knowledge of 
existing laws and regulations .The generic pharmaceuticals industry is under increased pressure 
from the Government and the FDA to comply with the rules and regulations governing the 
quality of its products and processes etc. This also means that the generic pharmaceutical 
manufacturers should select suppliers that are complaint with the FDA rules and regulations.  .  
 
Quality: FDA demands quality products from drug manufacturers. Therefore it compels the 
pharmaceutical firms to select suppliers ǁŝƚŚ ƐƵƉƉůŝĞƌ ?Ɛ ĐĞƌƚŝĨŝĐĂƚŝŽŶ ?proven record of world-
class service and quality raw materials. Quality management practices are vital in supplier 
selection strategies. 
 
 Risk: The supplier should have the ability to manage expected and unexpected risks that may 
occur. 
 
Cost: Cost has traditionally been considered as one of the most essential aspects of supplier 
selection criteria in the purchasing and supply management literature. 
 
Supplier Profile: This includes ƐƵƉƉůŝĞƌ ?Ɛ reputation, flexibility, capacity, financial health, and 
production facility.   
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Service: The level of services includes delivery time, value added services, and ease of 
communication ( Enyinda et al 2010 ) 
 
2.1.3. Determine Supply Strategy 
 
2.1.3.1. Portfolio Analysis-Supply Positioning: 
 
According to the Chartered Institute of Purchasing and Supply (CIPS,2008) supply positioning 
technique provides a mechanism for differentiating between the various categories of goods 
and services which are purchased and accordingly formulate specific strategies to meet the 
organizational needs with regard to each item or class of items. Thus accordingly supply market 
is segmented as  
 Tactical acquisition (low risk, low value),also called Non critical or generic 
  Tactical profit (low risk, high value), also called leverage, or commodities 
 Strategic security(high risk, low value), also called Bottleneck or critical 
 Strategic critical (high risk, high value), also called Strategic or Strategic Partnership 
Since the 4 quadrants have considerably diverse characteristics the purchasing goal and action 
scenarios will be different for each of them as given in figure 2 
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Strategic 
Security 
 
Strategic 
Critical 
 
Tactical Acquisition 
 
Tactical Profit 
 
Purchasing goal: Minimize 
attention  
 
 Length of contract: long 
 Supplier relationship: remote 
 Price management: formula or 
catalogue 
 Focusing on reduction of the 
process costs 
 Market complexity: many 
suppliers 
 Easy to switch suppliers 
 Business impact: low 
 
 
Purchasing goal: Guarantee 
supply 
 
 Length of contract: long 
 Supplier relationship: co-operative 
& collaborative 
 Price management: Indexation 
 Contract: detailed on the core-
points like price, quality, stock 
 Market complexity: limited 
suppliers 
 Not Easy to switch suppliers 
 Business impact: medium-high 
 
Value 
Business Risk 
 
Purchasing goal: Drive for 
profit 
 
 Length of contract: short 
 Supplier relationship: remote 
 Price management: market price 
 Contract: general terms and conditions 
 Drive for profit 
 Market complexity: lots of suppliers 
 Easy to switch suppliers 
 Business impact: low 
 
Purchasing goal: Closer supply 
management 
 
 Length of contract: medium-long 
 Detailed contracts 
 Supplier Analysis 
 Close control/development of supplier 
 Supplier relationship: collaborative 
 Price management: PPCA 
 Contract: very detailed 
 Contingency planning 
 Market complexity: limited suppliers 
 Not easy to switch suppliers 
 Business impact: high  
 
 
2.1.3.2. Supplier Preferencing: 
In the supply positioning model no consideration has been given to the approach and attitude 
of the individual supplier and the effect that this will have on dealings and the success or 
commercial interchanges. To ensure that supply positioning techniques are fully efficient this 
additional factor must be taken into consideration. The Supplier Preferencing framework allows 
for a company to consider how their suppliers perceive them (CIPS,2008). 
In defining supplier attitudes many organizations have shifted from traditional promotion of 
volume sales to a system called Key Account Management (KAM). 
Figure 2: Supply Positioning 
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In this the supplier estimates the true cost and thereby profitability of doing business with a 
customer for a particular product or service. In addition to the direct costs of production all 
other costs incurred in winning and retaining the business are calculated and aggregated. They 
will then use this information to decide on strategies to be applied while interacting with the 
customer. These strategies would range from vigorous defence, maintenance and 
development, to selective withdrawal. 
Here In the supply preferencing model the attractiveness of the customer is plotted against the 
relative value of the business (as a function of total sales).  
Thus accordingly the customers are categorised as nuisance, exploitable, development and core 
along with supplier objectives to deal with each category as shown below in figure 3 
 
 (Source: CIPS 2008) 
 
Figure 3: Supplier Preferencing Model 
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2.1.3.3. Market Management Matrix: 
 
By matching Supply positioning model with the supplieƌ ?ƐƉƌĞĨĞrencing model organizations can 
deduce whether the appropriate supplier has been selected for the particular business and 
what synergies or otherwise might exist as depicted in figure 
(Source:CIPS,2008) 
 
 
Figure 4: Market Management Matrix 
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Overall this technique serves to re emphasise the need for buyers to get into the habit of 
looking at key transactions from the point of view of supplier as well as their own. In this way, it 
becomes possible to predict responses and reactions to approaches from suppliers and to 
design the approach accordingly. 
 
 
2.1. 4. Identify Potential Sources 
 
Organizations should develop a preferred supplier list. Internal and external Databases should 
be analysed to identify potential sources .RFI's should be sent to collect data about new sources. 
Request For Information (RFI) is issued when the buyer seeks to gain market intelligence 
regarding alternatives and possibilities available to fulfill ƚŚĞďƵǇĞƌ ?ƐŶĞĞĚƐ ? 
Usually the buyer asks suppliers about the goods and services they could potentially provide, 
differentiating factor from other vendors in the marketplace, etc. With an RFI the buyer does 
not state a particular intention to give a contract.( Beil,D;2009).An RFI offers a relatively quick, 
inexpensive way to collect  information in a less formal manner than an RFP. It should be used 
to gather a large body of potential respondents ( Chronis,T,2007) 
 
2.1.5. Reduce Suppliers in Selection Pool 
 
Once a large body of potential sources is identified the buyer should then prequalify or reject 
suppliers using RFP or RFQ. 
 
2.1.5.1 .Overview of RFP [Request forProposal ] 
 
It is issued when the buyer has some knowledge about the market place and has a statement of 
work which contains a sĞƚ ŽĨ  “ƉĞƌĨŽƌŵĂŶĐĞ ? ĐƌŝƚĞƌŝĂ which it needs to be fulfilled. Suppliers 
respond to the RFP with information on how they would satisfy the ďƵǇĞƌ ?Ɛ ƉĞƌĨŽƌŵĂŶĐĞ
requirements and their price quotation. 
" An RFP is suitable for procurement of items/services that are non-standard or highly complex, 
requiring supplier input and expertise about the best way to meet the requirements set forth in 
the RFP"( Beil,D;2009 ).RFP is  sent to the vendors shortlisted  or top choice candidates. 
( Chronis,T,2007). 
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                                                                                                                 (Source: T  Chronis,2007  ) 
 
Figure 5: Use of RFI and RFP 
 
 
 
2.1.6.Conduct a Formal Evaluation 
 
At this point of process, buying firm has identified a set of suppliers that will go through a 
formal assessment process. At times the decision is based on a relatively easy comparison of 
competitive bids and at other times the decision is made only after a time consuming formal 
supplier assessment involving supplier site visits. 
 
2.1.6.1. Site Audits/Visits 
 
Due to the performance demands placed on suppliers and the high cost of switching suppliers, 
the use of site visits to evaluate supplier capabilities is an crucial part of the selection process. 
But these visits require a major commitment of time, budget and cross functional support. 
Though the cost of making worldwide site visits are high, the cost of making a poor selection 
decision is even worse .A buying firm should carry out due diligence by behaving as if was 
buying the supplier rather than buying the suppliers capabilities.(Trent,R,2007)) 
 
There are several supplier selection methods available in the literature. Some authors propose 
linear weighting models in which weights are assigned to the criteria in order to make a 
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distinction between criteria with different importance. The ƐƵƉƉůŝĞƌ ?Ɛ score are multiplied by 
these weights and a weighted score is computed for each one of them. ( Araz 2007).So far, the 
most utilized approach has been linear weighting models (Weber et al1991). These models 
consist of categorical, weighted point and the analytical hierarchical process (AHP). AHP has 
been most widely applied for the supplier selection problem ( Araz 2007). 
"Total cost approaches attempt to quantify all costs related to the selection of a vendor in 
monetary units, this approach includes cost ratio and total cost of ownership". (Tahriri,2007) 
Mathematical programming models often consider only the more quantitative criteria; 
this approach includes the principal component analysis and neural network.(Tahriri,2007). 
 
Among the various tools available for supplier selection two of the well knows methods which 
will be discussed next  are Kepner-Tragoe (KT analysis) , an industry recognized vendor selection 
tool and  Analytical Hierarchy Process (AHP), a practical decision support technique that has 
gained even deeper support in both academic as well as business communities. 
( Chronis,T,200). 
 
2.1.6.2. Kepner-Tragoe Analysis (KT Analysis) 
 
The Kepner-Tragoe Analysis is a methodology designed to help with decision-making. This 
structured approach is frequently used for the identification and grading of all known factors 
crucial to the decision making process. Here the goal is not to pick a single outcome, in-terms-of 
product, location, or service. Rather, one could look forward to select all feasibly viable 
options.( Chronis,T,2007). 
 
The Kepner-Tragoe process divides the decision making process into six logically oriented steps 
the details of which are discussed in appendix 1 
 
1. State the Purpose  
2. Establish Objectives  
3. Classify Objectives  
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4. Weight he Wants  
5. Compare Alternatives 
6. Choose the Best Course of Action 
 
 
2.1.6.3. Analytical Hierarchy Process: 
 
AHP is an acceptable decision support technique that has gained more support in the academic 
as well as business communities in recent years (Nydick, 2006). As a comparative tool, it is 
recognized as being a consistent, structured, and repeatable methodology that is critical to 
choosing external service providers.( Chronis,T,2007). 
 
AHP is a powerful and flexible decision making process to help organizations and individuals set 
priorities and make the best decision when one has to  consider both qualitative and 
quantitative aspects.It has been developed by Saaty (1980) for prioritizing alternatives when 
multiple criteria must be considered and allows the decision maker to structure complex 
problems in the form of a hierarchy, or a set of integrated levels .AHP offers a methodology to 
rank alternative courses of action based on the ĚĞĐŝƐŝŽŶ ŵĂŬĞƌ ?Ɛ ũƵĚŐŵĞŶƚƐ ĐŽŶĐĞƌŶŝŶŐ ƚŚĞ 
importance of the criteria and the extent to which they are met by each alternative. Therefore 
AHP is ideally suited for the supplier selection (Tahriri,2008) 
 
Generally, the hierarchy has t three levels: the goal, the criteria, and the alternatives. For the 
purpose of supplier selection, the goal is to select the best overall supplier. The criteria could be 
quality, price, service, delivery, etc. The alternatives are the different proposals supplied by the 
suppliers.(Tahriri,2008) 
The AHP approach, when applied to the supplier selection problem, consists of the following 
five steps (Nydick and Hill, 1992): 
"1. Specify the set of criteria for evaluating ƚŚĞƐƵƉƉůŝĞƌ ?ƐƉƌŽƉŽƐĂůƐ ? 
2. Obtain the pair-wise comparisons of the relative importance of the criteria in achieving the 
goal, and compute the priorities or weights of the criteria based on this information. 
3. Obtain measures that describe the extent to which each supplier achieves the criteria. 
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4. using the information in step 3, obtain the pair-wise comparisons of the relative importance 
of the suppliers with respect to the criteria, and compute the corresponding priorities. 
5. Using the results of steps 2 and 4compute the priorities of each supplier in achieving the goal 
of the hierarchy ". 
 
 
2.1.7. Select supplier and negotiate agreement 
 
Even after the thorough assessments the decision about selecting a supplier is not always clear. 
Cross-functional discussions &perspectives are needed in this step for critical items/services 
before reaching a final decision (Trent,R;2007). Part of this step includes how to reach 
agreement with targeted supplier. The negotiating process can be adversarial if not managed 
well. It would be disappointing for firms to go through the previous stages only to reach a 
deadlock at this point. 
The end of this step is only a start of what may eventually lead to a very long buyer-seller 
relationship. The focus of organizations should now change to managing and developing the 
selected suppliers. (Trent,R;2007)) 
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2.2 Risk Management 
 
dŚĞǁŽƌĚ “ƌŝƐŬ ?ŝƐĚĞƌŝǀĞĚĨƌŽŵƚŚĞ/ƚĂůŝĂŶǁŽƌĚrisicare, ǁŚŝĐŚŵĞĂŶƐ “ƚŽĚĂƌĞ ? ?/ŶƚŚŝƐƐĞŶƐĞ
risk is a choice rather than fate. (Emblemsvåg,J et al;2002) .Risk originated as a concept as early 
as 17th century and was initially associated with gambling. Its development through subsequent 
centuries saw its emergence in many fields, such as insurance and economics and more 
recently in engineering and science. (Mobey,A et al 2002). Risk taking is essential for human 
progress. In the past the ones who explored new lands, fought battles etc were risk takers. In 
the present eras changing economic conditions, however there are times where one has to go 
ahead and take risks and times to be risk adverse.  “ZŝƐŬ ŝƐŶŽƚ ũƵƐƚďĂĚƚŚŝŶŐƐŚĂƉƉĞŶŝŶŐ ?ďƵƚ
ĂůƐŽŐŽŽĚƚŚŝŶŐƐŶŽƚŚĂƉƉĞŶŝŶŐ ?(Jones and Sutherland, 1999). Most companies do not fail from 
mainly taking wrong decisions, but by not capitalizing on their opportunity. According to 
Drucker (1986) "the effective business focuses on opportunity rather than problems". 
Ultimately risk management is all being proactive 
 
Managing risk in projects is vital to success. It can help bring down the total project cost or 
timescale within acceptable limits of risks. It gives people a certain level of comfort in handling 
innovative projects even when it is not within their area of expertise. It enables firms to deal 
with more adventurous projects. (Kippenberger,T;2000) However Jablonowoski (200) highlights 
that managers seldom use formal risk analysis when making important business decisions. 
Identifying potential risks, estimating the probability of occurrence and the magnitude of 
consequences and thus the acceptability of the risk can present senior managers with 
important information that can be used to base their decision. (Mobey,A et al 2002) 
 
Gordon ( 2012) says  “ZŝƐŬ management (RM) is the process of looking into the future (short or 
long term) and asking what can go wrong and then doing something about it to prevent it from 
going wrong". According to Jafari et al (2011) RM is the "effort to optimize decisions in order to 
reduce uncertainty about future events when the information is incomplete, unclear or under 
discussion" .The risk management process refers to detecting weaknesses in methods used in 
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product development through a structured approach so that timely mitigation measures are 
undertaken to avoid risk, transfer risk, reduce risk likelihood or reduce the impact of risk (Risk 
Management Standard AS/NZS 4360, 1999). 
 
Institutions such as the Project Management Institute (PMI) and the Association of Project 
Management (APM) promote 'best practice' project management standards. As risks have the t 
potential to adversely influence a projects performance, the PMI acknowledges the risk 
management  as one of its nine key knowledge areas in its Guide to the Project Management 
Body of Knowledge (Project Management Institute,2004)."Project risk management, as one of 
the key disciplines of project management, is defined as the systematic process of identifying, 
analysing and responding to risk as project-related events, or managerial behaviour, that is not 
definitely known in advance, but that has potential for adverse consequences on a project 
objective" (Project Management Institute, 2004). Project risk management claims to enable 
project managers to effectively manage risk related information.Other than the PMI standards, 
there are several other Best practice project risk management processes such as the British 
Standards Institution (2000), the Office of Government Commerce (2007) or the UK Association 
for Project Management (2005). (Kutsch,E,et al) 
 
Overview of four well-known approaches to RM: 
 Project Management Body of Knowledge (PMBOK ) (Project management Institute,2004) 
  Project risk analysis and management (PRAM) (Association of Project Management, APM) 
  Management of risk (MOR)  
  The standard AS/NZS4360 (Standards Australia/Standards New Zealand, 2004) 
There is no major difference between them. The key stages of planning, identification, 
qualitative and quantitative analysis, reaction to risk, and controlling are present in all these 
approaches ( Jafari et al ;2011) 
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 (Source:Jafari et al;2011) 
 
Figure 6 : Comparison of approaches to RM 
 
 
 
2.2.1. Key steps in Risk Management 
I. Planning 
The process of making decisions and outlining the RM and its procedure 
 
II. Risk Identification 
Literature highlights numerous tools for risk identification. Such tools may be based on 
intuitive, inductive or deductive techniques. (Mobey,A et al 2002).The most simple and user 
friendly method to identify risks is through checklists. Checklists are a trivial method of risk 
identification where pre-determined crucial points are examined for symptoms of potential risk 
situation. The other known methods are Influence diagrams, Cause-and-effect diagrams, Failure 
mode and effect analysis, Fault trees, Event tree etc. (Ahmed,A;2007). 
 
III. Risk Analysis 
Risk is measured using two parameters i.e.; risk probability and risk consequence.  Risk 
probability or likelihood indicates a chance of a risk event occurring while risk consequence, 
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severity or impact represents an outcome generated from the risk event. Risk magnitude is the 
product of risk probability and consequence. To measure risk magnitude, probability and 
consequence of a risk event needs to be determined, which forms the risk assessment function. 
(Ahmed,A;2007) 
 
Risk can be analyzed using a Quantitative or a Qualitative approach. The quantitative approach 
relies on statistical calculation to determine risk, its probability of occurrence, and its impact on 
a project (Kleim,R;1998). In many instances, quantitative data is hard to attain and is restricted 
to very small area of the problem where historical trends could be sustained. Quantitative data 
is not always available when needed or not in the form required, hence a qualitative approach 
using subjective assessment techniques are often more appropriate for risk management. The 
subjective approach utilizes mainly the relative measures of human judgments, feelings and 
opinions. Though the subjective approach is influenced by individual bias, preferences and 
expertise, it provides a basis for risk assessment where it is more important to highlight risk 
events that are possible, rather than an exact prediction of a disastrous event. Organizations 
employ qualitative assessment techniques to identify risk because an expert opinion is the best 
source available, rather than an unreliable quantity. (Ahmed,A;2007) 
 
There are several formal techniques that can be used for risk analysis. A widely used model of a 
quantitative approach is decision tree analysis, applying probabilities to two or more outcomes. 
Another approach is the Monte Carlo simulation which generates a value from probability 
distribution and other factors. Others such as sensitivity analysis, probability analysis, multiple 
regressions etc are also based on quantitative analysis. (Kleim,R;1998) .However, for many 
projects less formal method is preferred. A well-known method used by project ŵĂŶĂŐĞƌ ?Ɛ for 
analysing and evaluating project risk is based on matrix-based decision model. An example of 
this is Probability and impact grids. "Risk events represented on a grid consisting of probability 
on one axis and impacts on another are often used to define threshold regions on the grid, 
which represent high risk events based on past experience or organizational 
procedures".(Cervone,H;2006) 
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IV. Response to risk 
It is the process of selecting and determining reactions in order to increase likely opportunities 
and decrease threats to a project. 
There are four basic ways to deal with risk: 
 Accept the risk-When nothing can be done to prevent or mitigate the impact of the risk 
  Adapt to the risk-Take measures that will mitigate the impact of the risks, also  called risk 
reduction 
 Avoid the risk- In order to keep a risk from seriously impacting the project 
 Transfer the risk-let someone else assume the risk circumstances. (Kleim,R;1998) 
 
Risk management considers in detail, all aspects of project management, so that all controllable 
events have an action plan or a risk mitigation plan. When a risk mitigation action is initiated 
after the risk events commence the approach is called as a reactive approach or a feedback 
approach. On the other hand, a pro-active approach or a feed forward approach refers to 
actions initiated based on chance of a risk event occurring, such as insurance. (Ahmed, A; 2007) 
 
V. Monitoring and control 
It is the   process of continuous monitoring of identified risk factors, controlling the existing risk 
factors and defining new risk factors. ( Jafari et al ;2011) 
 
 
According to Webster (1999), there are 4 steps to making project risk management explicit. 
1. Identify the risks 
2. Understand the impact that each risk event may have. 
3. Assess the likelihood of the events occurrence 
4. Plot risk matrix: Probability against  impact and finally decide on the responsive measures 
to be taken 
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Figure 7: Risk Matrix 
  
The author suggests to ignore the  low impact, low probability risks because the consequences 
though negative are insignificant, while every effort must be made to prevent high impact, high 
probability risks. Contingency plan should be made for low impact, high probability risks and 
finally controls should be put in place for early warnings in case of high impact, low probability 
risks.(Kippenberger,T;2000). 
 
 
According to Kliem (2008) very project that a company undertakes is prone to some or the 
other risks. But there are certain factors that expose projects to higher than normal risk. They 
are team size, history, management stability, resource availability, time compression, Staff 
expertise and experience &Complexity .It is suggested that all these factors must be taken into 
consideration before the onset of a project. 
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CHAPTER 3 
 
RESEARCH METHODOLOGY 
 
Research is a structured enquiry that utilizes acceptable scientific methodology to solve problems 
and create new knowledge that is generally applicable (Grinnell,1993).The use of appropriate 
research methodology is vital to the research process as the quality of the research findings is 
directly dependent on it.(Mouton &Maraias,1990). 
 
Market Research intends to provide the management with facts, information and insights that is 
needed to rapidly make the most efficient business decisions (Hamersveld and Bont, 2008). 
According to ( Hamersveld and Bont,2008)  the following Research Methodology is highly 
useful to gather reliable market information. 
 
Figure 8: Research Methodology 
 
 
Every single step described above plays a significant role in gathering reliable data 
 
3.1. The Research design 
 
It is the conceptual framework within which the research would be conducted. (Kothari ,2004). 
The purpose of research design is to provide for the collection of applicable information with 
minimal expenditure of effort, time and money. The following figure illustrates the research 
Design and the research techniques used at each stage in this Research 
Reliable 
Research 
Data 
Analysis 
Data 
Collection 
Data 
Collection 
Methods 
Respondent 
Selection 
Research 
Design 
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s An analysis of CRO selection process and Risk assessment for AstraZeneca Generic drug development project  
Study of Current Situation in pharmaceutical 
Industry 
China Macro environmental study for Generic product Development & 
Registration-PESTEL 
Initial understanding of AstraZeneca BM self-development project 
Map project key processes and highlight key strategic issues of AZ BM self-
development project 
Examine the CRO selection and evaluation process of this project in detail 
Analyse the supply strategy for 
Generic products 
 Perform Project Risk 
Assessment 
Supply risk Molecule risk Overall project risk 
Highlight                                                                                                     
generic business model of other big pharma in China 
Compare & Contrast AZ business model with others 
 Industry Reports +News 
articles +online sources 
Literature review +Interviews 
Literature review + Project reports 
+Interviews+ Analysis 
 
Project reports + AZ 
presentations+ interviews + online 
sources +literature review 
 
Project reports + AZ 
presentations+ interviews + online 
sources 
 
Project reports + AZ 
presentations+ interviews 
Literature review + Project reports 
+Interviews +Analysis 
 
Industry reports+ online 
sources 
Analysis 
              The Research intends to conduct a detailed analysis of the AZ BM self-development project highlighting key areas like CRO selection & evaluation and 
DVVHVVPHQWRISURMHFWULVNV7KH$=EXVLQHVVPRGHOLVWKHQFRPSDUHGDQGFRQWUDVWHGZLWKRWKHUELJ3KDUPD¶VWRVWXG\WKHSURVand cons 
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3.2. Respondent Selection 
 
This includes selecting the people who will be participating in the research. 
Professionals from AstraZeneca ICC (Innovation Centre China) were chosen to participate in the 
interviews. The emphasis was on communicating with the project leader and members directly 
involved in the AZ BM Self  WDevelopment project. 
 
 
3.3. Data Collection Methods & Data Collection 
 
 The data for this research was gathered by using both primary and secondary sources of 
information. 
 
Figure 9: Data Collection Method 
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3.3.1. Secondary Data 
 
In order to conduct this research, various sources of secondary data as illustrated above were 
reviewed consistently throughout the project. 
Secondary data are those data that have already been collected, analyzed, and made accessible 
from other sources (White, 2010).These data may or may not have been used to study the current 
problem at hand.(Hamersveld and Bont, 2008) .According to Aaker et al.(2008) the first step for 
researchers is to search for secondary data on the subject. 
 
Journals ,Books ,Internet sources were widely used to gather literature on  required topics like 
Current situation in pharmaceutical Industry ,shift towards generic drugs ,opportunities in the 
emerging markets ,China environment for development and registration of generic drugs 
,Supplier selection and evaluation processes, Risk management ,Generic Business models of big 
pharma companies and many other topics which have been discussed in the earlier section or will 
be referred to in the following sections. 
 
Company Archives which includes, project Documents, AZ presentations and AZ reports was 
regularly reviewed to gather information on the AZ Self-Development project details. Internet 
sources were also used to access AZ website, CRO websites to understand the functioning of the 
organizations. Online newspapers were regularly scanned to get updates on the latest 
development in the pharmaceutical industry .Eg-information on Pfizer-Hisun JV etc. 
 
3.3.2. Primary Data 
 
Primary data includes any information that one has collected and analyzed through means such 
as personal interviews, focus groups, surveys, tests and observations (Brodeur, C, 2012).This is 
generally a first-hand account of information that is collected by the researcher.  
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3.3.2.1. Interviews 
 
Interview was the only mode of collection of primary data in this research work. An appropriate 
mode of interview ensures that the respondents answer is not altered by the ambience of the 
interview, presence of other members of staff or senior member,   intricate nature of the 
questions etc .Interviews were held with AstraZeneca staff based in ICC China. Though the 
sample size was very small, significant amount of information was gathered as the interviewees 
were members who were very actively involved in the AZ BM Self-Development project. 
Personal Interviews were carried out, in a formal/informal setting. Semi-structured and 
unstructured interviews were considered ideal to collect information for this study. 
³Semi-structured interviews are non-standardized and are frequently used in qualitative 
analysis´'DYLG	6XWWRQ).The interviewer has a list of key themes, topics, issues and 
questions to be covered. In this type of interview the sequence of the questions can be changed 
depending on the course of the interview, additional questions can be put forth. Corbetta (2003). 
This type of interview gives the researcher opportunities to probe for views and opinions of the 
interviewee. Probing is a technique for the interview to explore new paths which were not 
initially thought of. (Gray, 2004 ). This mode of interview proved useful as the author was not an 
expert in the pharmaceutical Industry or Generic Drug Development and Registration area and 
provided opportunity to probe deeper into the subject by asking more open ended questions and 
gain better understanding of the project. 
 
Unstructured Interviews is non-directed and is a flexible method of conducting interviews 
.0LQLFKLHOOR HW DO  GHILQHG WKHP DV ³LQWHUYLHZV LQ ZKLFK QHLWKHU WKH TXHVWLRQ QRU WKH
DQVZHU FDWHJRULHV DUH SUHGHWHUPLQHG´ ,QVWHDG WKH\ GHSHQG RQ VRFLDO LQWHUDFWLon between the 
researcher and the participant. It is more casual than the aforementioned interview. Interviewees 
are encouraged to talk freely, frankly and give as much detail as possible. In this research 
unstructured interviews were regularly conducted during general conversations, lunch hours etc. 
This provided the author with valuable insights and additional information about subject matter. 
Unstructured Interviews have not been included in the interview due to their unpremeditated 
nature 
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Table 1:Interview Details 
 
 
 
 
 
 
 
 
 
  
Interviewee Industry Organization Designation Type of 
Interview 
Sessions Date 
 
Duration Data collection 
HaiHong 
Zhu 
Pharma AstraZeneca 
(China ICC) 
Sourcing Project 
Manager, China 
Semi-
Structured 
12 21/06/12 
22/06/12 
25/06/12 
28/06/12 
2/07/12 
4/07/12 
18/07/12 
23/07/12 
27/07/12 
1/08/12 
15/08/12 
22/08/12 
All of 
them 
have 
lasted 
for 
about 
30 mins 
to 1 
hour. 
Written Notes 
Dachen 
Cheng 
Pharma AstraZeneca 
(China ICC) 
Senior Manager 
Global Sourcing 
Team, China 
Semi-
Structured 
2 20/06/12 
15/08/12 
45 mins 
45 mins 
Written Notes 
Sarah Yan Pharma AstraZeneca 
(China ICC) 
Manager QA 
China 
Semi-
Structured 
1 23/07/12 10 mins Written Notes 
Esabelle Pharma AstraZeneca 
(China ICC) 
Manager 
RA 
Semi-
Structured 
1 16/07/12 30 mins Written Notes 
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CHAPTER 4 
CURRENT SCENARIO 
 
4.1. Current Situation in the Pharmaceutical Industry 
 
Global pharmaceutical companies have been built around the idea of discovering blockbuster 
drugs that solve various medical problems and sufferings of millions of people. But at present 
the traditional R&D model is facing many challenges. Patent expiries have caused drugs worth 
$15.3Billion face generic competition in 2011, this is expected to double to $33.2Billion in 
2012.Pharma companies can continue investing in new drugs, but the scenario is much more 
challenging than the past as today very few therapeutic area exist that are not addressed yet, 
thus implying that most newly developed drugs will be competing with existing ones. Moreover 
the rate of approval of new drugs has drastically reduced over the years due to stringent 
regulatory measures. Also the recent economic downturn has resulted in managed care 
organizations and employers pushing back on prescription drug costs and reimbursement.  
Internally, the number of molecules in pharmaceutical company pipelines is shrinking, and the 
risk/reward ratio for research and development activities is worsening. By and large, these 
trends have resulted in lower revenue and decline in profitability for most 'Big pharma' 
companies. Thus after having witnessed years of steady and predictable growth, the 
pharmaceutical industry now clearly entering a stochastic period.(Kandybin,A and  
Genova,V,2012) 
The ambiguity within the industry is evidenced by the different strategic moves the major 
companies have made with mergers, acquisitions, and divestitures in past few years. Apart 
from a few companies that have chosen to remain focused in branded pharmaceuticals most 
others have expanded into sectors such as diagnostics, consumer health, generic drugs, bio 
similars, nutrition, and wellness. (Kandybin,A and  Genova,V,2012) 
 
The two biggest generic drug market in the world ;the United States (45 per cent of global sales 
revenue ) and Europe (30 per cent of global sales revenue)  are characterized by high rates of 
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generic penetration, market saturation, intense competition and relatively less growth 
opportunities for the future. As a result, the large multinational companies are beginning to 
explore the untapped potential of emerging economies, like India and China. Low operating 
cost (infrastructure, material cost, labor cost), growing economy and a lucrative patient pool 
have made these nations a low cost outsourcing locations for drug discovery and development, 
clinical trials and drug manufacturing operations.( Chidambaram,A,2011) 
4.2. China Generic Industry 
 
The generic drugs market in China traditionally consists of two segments - active 
pharmaceutical ingredients and vanilla generics. The massive population growth and the 
outbreak of chronic disorders and communicable diseases have driven the government to 
resort to health care solutions that are cost effective. Thus, the China generic market has 
gained international status and supplies finished formulations and specialty generics.  The 
Chinese pharmaceutical market is currently valued at $42 billion, with generics being 
responsible for a significant share of 63 per cent. Branded and traditional Chinese medicine 
(TCM) constitutes the remaining 27 per cent. Skilled workmanship, sound infrastructure and 
compliance with the state Food and Drug Administration (FDA) gives China market comparative 
advantages over the western markets like the U.S. and Europe. The Chinese generics market is 
expected to reach $35 billion by 2015, thus making the future of generics drugs extremely 
promising. ( Chidambaram,A,2011) 
 
Despite the huge ďƵƐŝŶĞƐƐŽƉƉŽƌƚƵŶŝƚŝĞƐĂŶĚŐƌŽǁƚŚƉƌŽƐƉĞĐƚƐŽĨĨĞƌĞĚďǇŚŝŶĂ ?ƐŚĞĂůƚŚĐĂƌĞ
segment the constantly changing legal and market environments in China healthcare pose the 
biggest challenge to companies and executives functioning in this sector. The  highly complex 
supply chain, strong foothold of the local manufacturers and pricing pressure present 
significant challenges to big businesses. ƚƉƌĞƐĞŶƚŚŝŶĂ ?ƐŚĞĂůƚŚĞŶǀŝƌŽŶŵĞŶƚŝƐcharacterized 
by 2 distinctive characteristics: Severe disparities in the rural and urban healthcare systems and 
rising demand for superior drug quality. (KPMG,2011) 
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Most of the major Pharmaceutical companies are targeting the urban healthcare systems which 
comprises of 40% of the total patients. The rural market or the Broad market constitute the 
remaining 60% of the patients and are presently occupied by fragmented local generic 
competitors with no dominant players.  
Moreover in 2009 china launched an aggressive healthcare reform plan that intends to bring all 
its citizens under basic medical coverage, modernize its health infrastructure and improve 
grassroots healthcare delivery .The 12
th
 five year plan strives at achieving this through 
continuous reform and policy measures. From high end research to affordable drug pricing and 
sophisticated logistics and distribution all attempts are being made to modernize the China 
health industry (KPMG,2011) 
 
This scenario indicates opportunity for a major pharmaceutical player like AstraZeneca who has 
been putting down deep and broad roots in China for many years. Since its establishment in 
China in 1993 AstraZeneca has become one of the leading biopharmaceutical companies in the 
country with a turnover of more than $ 1 Billion in 2010.It has recently invested $ 230 million in 
building a manufacturing facility in Taizhou that complements its efforts to meet the medical 
needs of Chinese patients with medicines that are locally produced. This facility is currently 
under construction and will start operating by the end of 2014. The new will help AZ in reaching 
out to estimated 900 million people in urban and rural communities who have had less access 
to high quality medicines. 
AZ is presently looking to exploit the potential of the broad market by providing high quality 
generic drugs at a low cost. But for this it is necessary to develop a  thorough understanding of 
current china generic market trends ,dynamics,  capabilities and lay a high emphasis on various 
risks involved as AstraZeneca  has always been major player in branded drugs and  is totally  
new to the field of  Generic drugs. Thus a Macro environmental analysis; PESTEL is performed 
to gain a better insight on the impacts of various external factors on the future of generic drugs 
development and registration in China 
PESTEL Analysis for generic product development and registration in China is presented below 
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POLITICAL FACTORS 
Factor Trend Business Implication 
Healthcare reforms & 12TH 5 
Year plan 
(Appendix 2) 
Positive China 2009 healthcare reforms committed RMB 850B to bring its citizen 
under Basic medical insurance, modernize healthcare infrastructure 
&improve grassroots healthcare delivery thereby improving  healthcare 
accessibility and standards to a greater patient pool, a key driver for AZ 
Broad Market project. [Delloit (2011)] 
Health insurance scheme Positive In 2010 government introduced various health insurance schemes to 
cater to growing rural population boosting generic drug consumption 
Business environment/ 
Industry Consolidation 
Positive Chinese government encouraging M & A activities to consolidate the 
marketplace and improve the supply chain thus facilitating 
multinational companies  to gain access to the generic drug capabilities 
in the domestic market.(Xuan Yu,2010) 
Govt perception of Generic 
drugs 
Positive Generic drugs are increasing their presence as governments seek to 
limit spending on medicines and to encourage local production to 
decrease the reliance on imports 
Contradictory Goals Negative Government promoting growth of domestic pharma company and 
innovation at one hand yet aims to control drug spending to guarantee 
access for poor patients leading to market distortion. Current structure 
encourages pharmaceutical manufacturers to focus on competing on 
price rather than quality and innovation.[Chan,L., Daim,U.T; (2011)] 
Pricing controls Negative Increasing price control by the NDRC imposes constrains on the drug 
manufacturers 
Health Ministry mandates Negative Mandates that hospitals stock only one brand and one generic drug per 
new chemical entity, which restricts opportunities for foreign generic 
drug companies as they cannot compete with domestic manufacturers 
on the basis of price 
ECONOMIC  FACTORS 
 
 High Market Value 
Positive Chinese pharmaceutical market is valued at $42 billion, with generics 
accounting for a significant share of 63 per cent, indicating a huge 
opportunity for generic drugs developers.(Delloit,2011) 
 
Future Potential 
Positive The Chinese generics market is anticipated to reach $35 billion by 2015, 
making the future of generics extremely 
promising.( Chidambaram,A,2011) 
 
Economic Development 
Positive Vigorous economic development in China has given rise to rising 
disposable incomes among consumers, resulting in increasing 
expenditure on personal healthcare 
Healthcare Expenditure Positive China's per capita healthcare expenditures, having grown at a CAGR of 
19.3 percent from 2007 through 2010, are forecast to continue rising at 
a CAGR of 12.2 percent through 2015 , reaching US$437 per head in 
2016 .(Delloit,2011) 
 Market opportunities in rural 
areas 
positive The net income and private healthcare expenditure of rural 
households have grown sharply over the past two decades. MNC'S 
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have not been able to penetrate the small towns and the interior 
parts of China, thereby missing out on significant business 
opportunities. A key driver for AZ BM self-development project. 
Healthcare Payments Positive Historically, government healthcare payments in China have been lower 
than personal and private-sector payments, but they have been rising 
more rapidly, and are forecast to equal or exceed private payments in 
2013 
SOCIAL FACTORS 
Demographics Positive ŚŝŶĂ ?ƐĚĞŵŽŐƌĂƉŚŝĐƐǁŝůůĚƌŝǀĞƵƐĂŐĞof generic ĚƌƵŐƐ ?ĂƐƚŚĞĐŽƵŶƚƌǇ ?Ɛ
population continues to grow and age. Elderly consumers who have 
greater need for healthcare services and facing drops in income will 
support future sales of generic drugs in consumer health. 
Currently, the elderly population makes up 23 to 40 % of the 
prescription drug market and 40 to 50% of the OTC drugs market. 
(Consumer health in China,2012) 
 Medication Pattern Positive Self medicating tendency of  Chinese consumers  is a key driver for 
generic drug sales 
Shift of focus towards quality Positive Growing demand for superior drug quality among consumers is a 
opportunity for AZ which is focusing on producing high quality generic 
drugs  
Changing preferences Positive Many consumers have shifted their preferences and purchasing 
priorities. They save money by paying low prices for basic medicines 
and then later use that money to buy luxury goods, thus generic drugs 
which are much cheaper than the branded drugs is preferred. 
(Generic drugs in consumer health global overview ,2011) 
Lifestyle diseases Positive Increased prevalence of diseases associated with western lifestyles will 
drive consumption of these drugs 
Foreign Brands Positive As Chinese consumers have high confidence in foreign brands, these 
brands are expected to win drug customers away from the domestic 
generic brands, causing their proportional market shares to shift 
accordingly. 
     TECHNOLOGICAL  FACTORS 
Inherent competencies Positive Multinational generic drug companies can leverage the excellent 
reverse engineering skills of the Chinese scientists and chemists at 
almost one third of the cost incurred in the developed nations, thereby 
gaining high profit margins. 
Attractive R&D outsourcing 
destination 
Positive CROs in China have improved infrastructure, increased compliance with 
international standards, and access to untapped manpower and reduce 
ƉƌŽĚƵĐƚƐ ?ƚŝŵĞĂŶĚĐŽƐƚƚŽŵĂƌŬĞƚ ?ĂŬĞǇĚƌŝǀĞƌĨŽƌD
project.[Chan,L., Daim,U.T; (2011)] 
Sourcing Risk Negative The outsourcing activities in China often gives rise to quality issues as 
there is a risk of adulterated API, drug intermediaries, excipients 
entering the supply chain 
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Complex Drug Distribution 
System 
Negative Pharmaceutical distribution in China is highly fragmented, and often 
criticized for its inefficiency and lack of transparency 
     ENVIRONMENTAL   FACTORS (COMPETITIVE) 
Domination of local 
participants 
Negative 98 % of generic drugs market controlled by local participants as a result 
of their wide geographical coverage, strong distribution network, and 
aggressive promotion methods and close association with the local 
government on a commission based model.( Chidambaram,A,2011) 
Strategic alliances  International Pharmaceutical companies increasing ties with generic 
counterparts in China to bring affordable consumer health products to 
market 
Market Status Positive Generic drugs market in China has gained international status and 
supplies finished formulations and specialty generics 
     LEGAL/REGULATORY   FACTORS  
   
Increasing compliance with 
the state FDA and GMP 
Positive Due to the adverse effects caused by several high profile incidents 
pertaining SFDA revised regulatory measures are now taking shape to 
introduce a higher level of transparency, limit the discretion of 
individual officials and raise the standards for the registration of 
pharmaceuticals. 
Regulatory Bureaucracy Negative Increased Bureaucracy on the New Module of Regulatory Three-
Party Balance makes the registration process very complex 
9 Dossier reception Office (Administrative Acceptance) 
9 Dept of Drug Registration: DDR (Regulatory Approval) 
9 Centre for Drug Evaluation :CDE (Technical Review) 
Registration process Negative Stringent & long regulatory approval processes for generic drugs 
involving a number of regulatory bodies at various levels of 
government, and at various regional levels.(Delloit,2011) 
Approval Rates Negative Low approval rates for Class 6 drugs due to 
9 Large number of generic drug applications received by the 
SFDA   
9 Significant  human resource shortage in CDE to review the 
application 
9 Stand taken up by the government to promote innovation 
rendering the development of generic drugs as undesirable. 
Regulatory complications Negative Constant change/update on regulations (1999, 2002, 2005, 2007) makes 
registration process very tedious and complicated 
Also no rolling submission is allowed in case of Generic Drugs. 
Intellectual Property (IP) 
issues 
Negative IP  issues(both formulation &process) that are prevalent in China 
imposes a huge challenge to MNCs developing Generic drugs 
Branding Issues Negative As it not permissible in China to give brand name for the generic drugs 
differentiating ones product is a challenge 
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Thus the macro environmental study reveals enormous opportunity in China along with 
significant challenges for the AstraZeneca Generics drugs Project, also called the Broad Market 
project. 
 
4.3. Scope of AstraZeneca China Broad Market (AZ CBM)project  
 
The AZ CBM projects consist of 4 major activities: 
 
4.3.1. To launch generic drugs business with existing AZ products suitable for BM 
 ?ƐƉƌŽĚƵĐƚƐ Betaloc, Plendil, Bricanyl, LosecMups ,Rhinocort,Barnyl& Bambec are  already 
being tried out in the Broad Market 
.  
4.3.2. To Import from Indian partners  
 20 molecules are to be imported from India through Aurobindo and Torrent, Indian 
manufacturers, who have signed a 4 years exclusivity contract with AZ. Due to the uncertainties 
of India sourcing (very low successful approval rate for import class 3 drugs), self-development 
of   8 molecules will be considered and implemented in parallel with India sourcing 
 
  
 Packaging  
 
 
 
4.3.3. M & A activities 
AZ intends to acquire Chinese companies that own the manufacturing Licenses of required 
molecules. This is a Critical step towards jumpstarting the BM commercial machine. 
AZ has acquired company ' Garnet 'and has obtained rights to 3 molecules from them. 
 
 TT 
  
India  
Import class 3 
drugs 
AZ  newTaizhou 
Site 
   Garnet 
3 molecules CMO Lijian AZ new Taizhou Site 
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4.3.4. Self-Development project- 
 
This is the focal point of this report. 
The scope of the project is to select the suitable CRO to develop 15 OSD and prepare dossier for 
Regulatory approval. 
There are two key elements to measure the success of the self-development project 
1.  Successful Technical Transfer (TT) to the new Taizhou site. 
2.  To get Regulatory approval which includes BE study approval 
and LML (Local Manufacturing License) approval. 
 
The Process flow chart below (figure 10) depicts the various stages in the development of 
generic drugs for the Self development project along with the approximate time frame for 
executing each task.  Next the strategic issues in each stage of development are discussed. 
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Figure 10: Project Key Process 
 
 
 
 ?API suppliers screened & shortlisted by CRO  
 ?CRO collects sample and conducts QC test 
 ?AZ makes final decision based on test reprts and  site inspection 
Raw material sourcing: 
API 
& Excipients 
[3 - 6 Months] 
 ?Preformulation,Formulation,analytical,scale up studies etc have to be 
performed by the CRO in its site,but AZ will review the progress at 
every stage and take the final call. 
CRO : 
Process Development 
[10 Months]  
 
 ?CRO will perform  TT to the new AZ site in Thaizu for Large scale 
manufacturing. 
 ?6 Sample batches production and Process Validation  at AZ new site 
 ?CRO & AZ  scientists in Thaizu will  work jointly towards achieving this 
 
TT   &  Sample Batch production 
[6 Months] 
 ?Accelerated stability  test Performed on three Batches 
 ?Dossier preparation by CRO based on AZ guidance 
IND Stability study &  Filing  
[6 Months] 
 ?AZ  reviews & submits the Dossier to  SFDA 
 ?Pre approval inspection (PAI) mock test conducted by AZ to prepare 
the CRO 
 ?Onsite inspection  (PAI) by Taizhou SFDA,Collect sample & send to IDC 
 ?CDE review reports of PFDA & IDC 
 ?CDE forwards findings to SFDA for approval 
Dossier  Submission   to SFDA  & 
evaluation 
[10-14 Months] 
 ?Bio equivalence study Conducted in institute named  SIMM 
 ?No of trial subjects: 60 
CTP approval & BE  Study 
[6 Months] 
 
 ?Submission of the BE study report to SFDA by AZ 
 ?Evaluation and sanction of Local Manufacturing License by SFDA 
 
Evaluation & 
LML Approval 
[upto 20 Months] 
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It can be observed from the Self -development process flow chart that even though CRO is 
actively involved in each and every stage of the process, the final decision on the progress of 
every step is taken by AZ team. It actively monitors and performs Quality Assurance and project 
management activities throughout, right from the start until the final approval process. 
It will take AZ about 4 1/2 to 5 years to complete the entire process 
 
 
4.3.4.1. Key Strategic Issues 
 
1. Raw Material sourcing 
The API and excipients are to be sourced from domestic manufacturers in China  
 
Advantages of sourcing from China 
 Cost Advantage 
 Easy access to a wide variety of intermediates and chemicals. 
 Availability of  massive scale and capacity in China ,as well as better infrastructure 
 China has a huge pool of capable, talented scientists and engineers. 
 Increase in the number of U.S. FDA inspected facilities in China over the past few years 
and companies are continuing to invest in quality upgrades. 
 Chinese government continues to invest strongly in the local manufacturing industry. 
(CPhl,2011) 
 
Threats 
 
 There have been cases of new risks from drugs; that of unsafe ingredients entering the 
supply chain as drug makers increasingly outsource the production of API s to third 
parties. Thus if vigilance is not maintained there is a risk of adulterated API ,drug 
Intermediates ,excipients entering the supply chain.  
 A lack of senior level talent in areas like quality assurance and project management. 
(CPhl,2011) 
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 Salaries in China are increasing much faster when compared to the western markets. 
 Environmental compliance is a major cost and many factories that cannot invest in 
adequate upgrades are closing. 
 Also there is also a pervasive focus on short-term rather than long-term returns. 
 Regulators are increasingly asking more about Carryover of Impurities & Solvents to API, 
etc. 
 
 
2.  CRO: Process development 
 
The CRO plays a pivotal role in the development, manufacture and registration of 
generic drug in the AZ BM self-development project 
 
Advantages of CRO 
 ZĞĚƵĐĞƐƉƌŽĚƵĐƚƐ ?ƚŝŵĞĂŶĚĐŽƐƚƚŽŵĂƌŬĞƚ ? 
  Improved infrastructure, technical knowhow and  better educated staff 
  Increased compliance with international standards 
 Have good connections with governments, research institutes, and universities. 
 Better understanding of the environment in which they operate. (Chen et al., 2008). 
  
Threats 
 High set up cost 
 Control and monitoring issues 
 Information leak or  misuse 
 Quality Concerns 
 Delay in service 
 Challenges in development, 
 Challenges in defining  manufacturing process  
 
3 .Technical Transfer & Sample Batch preparation 
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x Capacity constrains 
                       TT of only one or maximum two ODS's can be performed at any one time in the 
new manufacturing site in Taizhou due to capacity and resource constrains.  TT process takes at 
least 6 months to complete. 
 
x Scale up issues 
In the CRO site only small to intermediate scale of the drug formulation is prepared, In the AZ 
site for the purpose of large scale manufacturing about 500 Kg's have to be prepared. This scale 
up activities can a times lead to unprecedented challenges. 
 
x The AZ Taizhou sit will be ready only by early 2014; therefore Technical transfer cannot take 
place until then. 
 
4. Stability study and Filing preparation 
 
x Risk of failure of stability studies 
x Complex attribute of  CMC dossier filing  
 
5. Dossier Submission to SFDA and Evaluation 
 
 
x Long and stringent evaluation procedure. 
x Many applications waiting in line 
x Involvement of different levels of government ;Provincial, State ,Central 
x Significant resource shortage in SFDA   causing longer time for evaluation  
x Constant SFDA middle level staff change and  role rotation policy reduces the effectiveness 
x Increased Bureaucracy on the New Module of Regulatory Three-Party Balance 
x Difficult and Unexpected question raised by SFDA during inspection 
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x Window opportunity to talk to Taizhou FDA as AZ has invested a huge amount of money 
($230 million) in the new Taizhou site. 
 
 
6. CTP Approval & BE study 
 
x BE study  can be performed in a shorter duration of 6 months when compared to clinical 
trials 
x China has Generics dominated industry with rich BE experience 
x Mature BE study environment: experienced personnel's, qualified sites and advanced equipment on 
HPLC, LC-MS etc. & Conformance to GCP requirement 
x BE study failure risks which may be due to one or more of the following reasons 
o Failure to follow Protocols  
o Inadequate Analytical Validations  
o Failure to assure data accuracy, proper dosing 
o  Inadequate Controls on CRO -Audits, Monitoring 
 
 
  7. Submission and LML Sanction 
 
x Low approval rates for class 6 drugs 
x EĞĞĚĂ ‘ƐŚŝŶŝŶŐ ? (differentiating) point for AZ  generic  drug ,something that gives it an 
advantage over other generics 
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                                                    CHAPTER 5 
                                                 DATA ANALYSIS  
 
The key aspects of the Self-Development project  are CRO selection and evaluation, molecule 
assessment and overall project risk assessment, all of this will be discussed this analysis section 
of the report. 
 
5.1. CR0 SELECTION AND EVALUATION  
 
In the AZ CBM self-development project CRO is involved right from preformulation activities, 
formulation development through tech transfer, up to the attainment of LML. So it is evident 
that a CRO has a vital role to play in the successful execution of the project. Since AZ is new to 
generic drug development and registration, it is very vital to find a CRO with suitable skills and 
capabilities to take a lead role in the execution of the project. Thus a very High emphasis laid on 
the CRO selection process. 
 
5.1.1. Scope of CRO work 
 Preformulation&Formulation development 
 Technical Transfer to AZ new site  
 Pilot batches production and Process Validation production at AZ new site.  
 Dossier preparation for LML (Local Manufacturing License) submission.  
 Prepare supporting data and documentation during LML application period.  
 
5.1.2. Criteria for selection 
The AZ project team has laid down several important criteria that a potential CRO has to meet 
before being selected. 
They are: 
 Technical 
o Formulation Sciences 
o Biopharmaceutical Sciences 
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o  Analytical Sciences                                                    
 Regulatory 
 Quality  
 Financial 
 Cost 
 Project management 
 Sourcing & commercial 
 Suitability(Overall project suitability inclusive of soft factors like strategic commitment, 
strategic direction, Management  compatibility, responsiveness, transparency, conflicts of 
interest etc) 
All of these factors will be important in eventually defining the success of the project and every 
possible effort has to be taken to test the potential CRO s in the above mentioned grounds. 
 
5.1.3. Selection Process 
 AZ has followed a structured and tedious CRO selection process for the China Broad Market 
Self Development project which is summarized below in figure 11. The details of the process 
are explained next. 
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Figure 11 :Summary of CRO selection process 
 
 
STEP: 1    
On the basis of information collected through Market Intelligence i.e; through company 
contacts, internal information & internet information Request for information (RFI) was sent 
out and initially 9 potential CROs were selected by the project team.  
As discussed in the literature review RFI provides an initial understanding of the capabilities of 
the CRO s being screened for the project. The questionnaire includes commercial, technical, QA 
(Quality Assurance) and planning & staffing questions. In order to protect company's interests 
STEP 1-MI ,RFI 
and  CDA 
9 CROs 
selected 
STEP 2-RFP sent  
6  CRO 
responded 
STEP 3-RFP 
screening &QA visit 
4 CROs 
seleted 
STEP 4-KT 
analysis 
3 CROs 
selected 
STEP 5-Cross 
functional Audit 
2 CROs 
Finalized 
for the pilot 
project 
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and information confidentiality agreement (CDA) is signed with 9 potential suppliers. Once this 
process is completed both suppliers and AZ can disclose relevant information that is necessary 
for the project. 
 
 
 
Figure 12 &ODVVLILFDWLRQRIWKHSRWHQWLDO&52¶V 
 
 
 
As seen above these 9 shortlisted ZK ?Ɛ operate under different business models. Therefore 
they also have different research and manufacturing capabilities .Pure CRO generally have good 
ƌĞƐĞĂƌĐŚĐĂƉĂďŝůŝƚŝĞƐĂŶĚůŽǁƚŽŵĞĚŝƵŵŵĂŶƵĨĂĐƚƵƌŝŶŐĐĂƉĂďŝůŝƚŝĞƐ ?DK ?ƐŐĞŶĞƌĂůůǇŚĂǀĞŚŝŐŚ
manufacturing capabilities and low to medium research capabilities. Research and Academic 
institutions have very good research capabilities and low manufacturing capabilities. Eminent 
generic players having a firm foothold in the market may have high to medium research and 
manufacturing capabilities 
 
 
 
 ?WUXIAPPTEC 
 ?SUNDIA 
 ?SCIENPHARM 
 ?VENTUREPHARM 
 CONTRACT RESEARCH 
ORGANIZATION (CRO) 
 
 
 ?HISUN 
 ?QILU PHARM 
 ?HUA HAI PHARM 
 
 
EMINENT GENERIC PLAYERS 
 ?NOVAST CONTRACT  MANUFACTURING 
ORGANIZATION (CMO) 
RESEARCH & ACADEMIC 
INSTITUTE 
          Shanghai Instutute of Meteria Medica (SIMM) 
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dŚĞƉƌŽďĂďůĞĐĂƉĂďŝůŝƚŝĞƐŽĨƚŚĞ ?ZK ?ƐĂƌĞĚĞƉŝĐƚĞĚďĞůŽǁ in figure 13. 
 
Figure 13: Capability Estimation 
 
AZ is looking for a service provider with high research and medium to high manufacturing 
capabilities which are vital for the successful execution of the project. 
 
 STEP: 2 
 
 Request for proposal (RFP): As discussed in the literature the purpose of this document is to 
invite Providers to submit a fully priced and detailed proposal for the provision of an Oral 
Immediate Release (IR) Tablet Development and Manufacture. 
Through RFP AZ will provide the requirements. The suppliers will use their professional 
technical knowledge and innovation to develop the product and provide budgetary quote as 
well. 
As an outcome of project team decision two molecules, Valsartan &Telmisartan were selected by 
the project team for RFP due to their high market value and technical barriers to test the 
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development, technical and regulatory capability of the 9 potential CROs. Molecules are 
allocated based on the capability knowledge gained from PD China experience with CROs. As 
Telmisartan was more challenging to develop it was assigned the CRO s whose complete 
capability was not ascertained yet. Sundia and Hisun displayed a keen interest to work on both 
the molecules clearly indicating their commitment and pro activeness towards the project 
 
  
Table 2: Molecule Allocation 
CRO  Molecules allocated  
Wuxi Apptec Valsartan 
Sundia Valsartan 
&Telmisartan 
Hisun Valsartan 
&Telmisartan 
Qilu Pharm Telmisartan 
Novast Valsartan  
SIMM Telmisartan 
Scienpharm Telmisartan 
HuaHai Pharm Telmisartan 
Venturepharm Telmisartan 
 
 
  
  The project team received responses from 6 potential CROs to the RFP.  
Three companies declined RFP 
¾ The generic players, Qilu Pharm &HuaHai Pharm declined RFP due to conflict of interests 
as it probably wants to develop its own formulation in-house. 
¾ SIMM,the institution declined  RFP as it did not believe that AstraZeneca which was a 
well-established innovator drug company had the required skill sets to outplay the generic  
drug industry of China which is wholly dominated by domestic  players competing on the 
basis of price      
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STEP: 3 
RFP Screening: Based on the response to quality questionnaire in the RFP it was found that 
there was no certified QM system & SHE system in Sciencepharm & Venturi Pharm& there was 
no certified SHE system in Sundia, moreover AZ did not have  any prior knowledge of 
scienpharm and venturipharm. Therefore QA visits were arranged to, Venture pharm, 
Scienpharm& Sundia. 
Based on QA visits only Sundia was found applicable for the project from QA point of view and 
the remaining two were eliminated as their facilities were substandard and did not meet AZ s 
necessary criteria. 
dŚƵƐ ?ZK ?Ɛ ?^ƵŶĚŝĂ ?tƵǆŝƉƉƚĞĐ ?,ŝƐƵŶĂŶĚEŽǀĂƐƚĂƌĞƐŚŽƌƚůŝƐƚĞĚĨŽƌƚŚĞŶĞǆƚƐƚĞƉ ? 
 
STEP 4:  
KT (KepnerTregoe) analysis tool which has been discussed in the literature review was used to 
perform a cross functional evaluation of the suppliers based on the information provided in the 
RFP. 
 
 Criteria for Selection 
The criteria are divided into two basic categories.  
(1) MUSTS: Criteria that must be achieved in order for the effort to achieve a high probability of 
success. These criteria are classified as Dh^d^ĂŶĚĂƌĞĂďƐŽůƵƚĞǇĞƐ ?ƐĂŶĚŶŽ ?Ɛ ?dŚĞŝŶĂďŝůŝƚǇŽĨ
an alternative to meet the requirements is considered a fatal flaw. 
(2) WANTS: Those that are critical to achieve a viable outcome but are accepted in lesser 
degrees. There criteria are viewed as WANTS.  
 
Must Criteria 
1. Financial stability 
2. Tablet development capability (wet and dries processing) 
3. GMP/GLP certification 
4. Appropriate SHE standards 
5. Experience and capability in stability storage and testing 
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6. Pass AZ QA audits 
7. SFDA Generic filing experience 
dŚĞƐĞĐƌŝƚĞƌŝĂĂƌĞǀŝƚĂůƚŽƚŚĞƉƌŽũĞĐƚĂŶĚŵƵƐƚďĞĨƵůĨŝůůĞĚďǇƚŚĞƉŽƚĞŶƚŝĂůZK ?Ɛ 
 
Table 3: KT analysis: Must criteria 
 
 
 
To assess the financial stability of the companies 5 important factors as depicted in the table 
has been analyzed .Each of the factor has been given a weight of 20%. 
WuxApptec and Hisun, both of them being a public listed company have presented all 
necessary financial facts and figures which show a good financial stability and have scored a sub 
total of 4.4 and 4.2 out of 5 respectively. On the other hand Sundia, a privately owned company 
has not given all necessary information, scoring a low sub total of 2 out of 5.Novast has not 
provided any relevant financial information at all, thus scoring 0. 
ZĞƐƚŽĨƚŚĞĐƌŝƚĞƌŝĂ ?ƐŚĂǀĞďĞĞŶŵĞƚďǇtƵǆŝƉƉƚĞĐ ?^ƵŶĚŝĂ  ?,ŝƐƵŶĞǆƉĞĐƚĨŽƌEŽǀĂƐƚǁŚŽŚĂƐ
not provided any information about its GMP/GLP certification,  SHE standards and has not 
Undergone AZ QA audit. 
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Want Criteria  
The methodology followed here is to compare total weighted capability of a supplier with total 
weighted cost as shown below. 
Capability is assigned 100% weight and has the following sub categories, each assigned with a 
separate weight based on the decision of the project team 
 Formulation Sciences  :25%w 
 Analytical Science         :20%w 
 Bio pharmaceutics   :05%w 
 QA   :15%w 
 Regulatory experience  :25%w 
 Project Management :10%w 
This is then measured against cost (100%) and evaluated accordingly 
The dashboard of KT analysis is given below (For a detailed break up of capability evaluation of KT analysis 
refer appendix 3) 
 
Capability: 
 
 
 
 
                  Table 4: CRO capability assessment 
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Hisun scores the highest in formulation sciences (22%), QA (10%), Regulatory (18%), bio 
pharmaceutics (3%) and project management aspects (7%) followed by an above average score 
in analytical sciences (15%) and thereby attain the highest total weighted capability of 75%. 
 
WuxiApptec scores the highest in bio pharmaceutics (3%) ,analytical (18%) aspects ,above 
average score in formulation sciences  (15%),QA(9%) aspects, average score in project 
management (5%) and a below average score of 9% in regulatory aspects altogether attaining a 
second highest total weighted capability of 59%. 
 
Sundia gains highest score in bio pharmaceutics, above average scores in analytical (14%), 
formulation sciences (15%), average score inproject management (5%)   and a below average 
score in QA (8%) & regulatory aspects (10%) altogether reaching a total weighted capability of 
53%. 
Novast attains a above average score in formulation sciences (15%)& QA(9%) ,average score in 
analytical sciences(10%),below average scores in Regulatory(8%),bio pharmaceutics(1%) and no 
definable project management plans(0%) thereby scoring the lowest total weighted capability 
of (43%) which falls much below the minimal required  average of-50% 
 
Cost: 
 
 
 
 
Sundia has the highest cost advantage (95%) followed by Novast (77%), Wuxi (63%) and Hisun. 
 
                        Table 5: CRO cost assessment 
Shraddha Shetty Page 60 
 
Capability versus Cost advantage: 
 
 
 
                
 
 
 
Hisun has the highest capabilities (75%) which are significantly higher than WuxiApptec (59%) 
but its cost advantage is the least. But the sheer presence of such high capabilities places Hisun 
in the top. 
WuxiApptec in spite of having second highest capabilities is moved to the 3rd position in the 
overall scoring because its cost advantage is very low,  whereas Sundia has a very significant 
cost advantage (95%) and small difference in capabilities (55%) when compared with 
WuxiApptec (59%) thus placing it in the 2nd position. 
 
59 
55 
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Capability Cost advantage
Table 6: CRO capability cost comparison 
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Thus ĨŝŶĂůƌĂŶŬŝŶŐŽĨƚŚĞZK ?ƐĂĨƚĞƌ<dĂŶĂůǇƐŝƐŝƐ 
Hisun  :  1st 
Sundia  : 2nd 
Wuxi Apptec : 3rd 
Novast  : ELIMINATED 
 
BeforĞƉƌŽĐĞĞĚŝŶŐƚŽƚŚĞĨŝŶĂůĞǀĂůƵĂƚŝŽŶŽĨƚŚĞZK ?ƐŬĞǇĨĂĐƚƐŽĨƚŚĞĐŽŵƉĂŶŝĞƐĂƌĞĚŝƐĐƵƐƐĞĚ 
 
SUNDIA  
SundiaMediTech , Ltd.  Is a contract research company headquartered in Shanghai, offering 
drug discovery and development services. It was founded by a group of veterans from the US 
biopharmaceutical industry in 2004.Its operation facilities are located in China and US .The 
ŽŵƉĂŶǇ ?Ɛ ĚƌƵŐ Ěiscovery and research services include integrated drug discovery services, 
medical chemistry, discovery biology, organic synthesis and parallel synthesis, and drug 
metabolism and pharmacokinetics. Its pharmaceutical development services consist of chemical 
development, quality assurance and regulatory affairs, high potency drug development, pre-
formulation and formulation, and analytical development. The company focuses on 
strengthening its scientific collaboration with its partners, clients and investors for the new 
drug discovery and development processes.Sundia has a strong customer base in the domestic 
market.(Nexis UK,2012) 
Its experienced formulators ĂŶĚĂŶĂůǇƚŝĐĂůƐĐŝĞŶƚŝƐƚƐŚĂǀĞƵƉƚŽ ? ?ǇĞĂƌƐ ?ĞǆƉĞƌŝĞŶĐĞŝŶŐĞŶĞƌŝĐ
product development .On-going generic projects are in the development, technical transfer, 
scale up and pilot batch stages. 
 
Relationship with AZ 
^ƵŶĚŝĂ ŚĂƐ ďĞĞŶ ĂĐƚŝǀĞůǇ ƉĂƌƚŝĐŝƉĂƚŝŶŐ ŝŶ ƐĞǀĞƌĂů ŽĨ  ?Ɛ ƉƌŽũĞĐƚƐ ĚŝƌĞĐƚĞĚ ŝŶ ŶŝĐŚĞ ĂƌĞĂƐ
pertaining to supply of drug substance since 2008.For the AZ BM Self-Development project it 
has been conducting Market Research on the 15 formulations covering all product related 
information, IP issues, API sourcing Risk assessment etc. 
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 WUXIAPPTEC 
Established in December 2000, WuXiAppTec is a global pharmaceutical, biopharmaceutical, and 
medical device research and development outsourcing company with operations in China and 
the United States .Wuxi is listed in the New York Stock Exchange  
The company provides a wide and integrated portfolio of manufacturing and laboratory 
services for medical device and R&D process. Wuxi offers a broad range of services and 
solutions for pharmaceutical, biologics, medical devices, toxicology and combination products. 
The company provides discovery and development services to pharmaceuticals; development, 
testing, manufacturing and virology services to biologics; proof of concept, process and product 
development, medical devices testing services and services for tissue products to medical 
devices; pre-clinical toxicology testing and toxicology testing for devices and combination 
products to toxicology; and product testing and manufacturing to combination products.  
Wuxi is a well know brand in the area of Innovative drugs, but does not have relevant 
experience in the field of Generics 
FACT SHEET: SUNDIA 
 
 Established: 2004 
 
 Headquarters: Shanghai 
 
 Locations: Shanghai 
 
 Working with AZ since: 2008 
 
 No .of AZ projects: 16-20 
 
 Ownership: Private 
 
 Business Model: Pure service provider, CRO 
 
 Project team: 5-6 
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Relationship with AZ 
Wuxi has been working with AZ since 2005.But AZ and Wuxi experienced a rough phase 
between 2005 to 2008.There were several issues concerning project management, filing of RFQ 
etc which did not meet AZs required standards. The projects undertaken during this period of 
time did not fare very well .But after AZs active involvement, guidance, training & supplier 
development measures these problems were contained .AZ cleared the communication gap, 
addressed the cultural differences and worked with Wuxi to bridge the performance gap. As a 
result from 2008 onwards there has been a smooth operation of projects. Since the companies 
have successfully transitioned this difficult phase they would be better aligned to work on 
future projects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACT SHEET: WUXIAPPTEC 
 
 Established:2000 
 
 Headquarters: Shanghai 
 
 Locations: Shanghai, Tianjin &Jiangsu Province 
 
 Working with AZ since: 2005 
 
 No .of AZ projects: About 20 
 
 Ownership Public, listed on New York stock 
exchange 
 
 Business Model: Pure service provider, CRO 
 
 Clients: Bristol-Myers Squibb, Fujitsu, Elisa 
Technologies, Qiagen N V are some of its major 
clients 
 
 Employee count:6000 
 
Project team: 10 
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HISUN 
Founded in 1956 Zhejiang Hisun Pharmaceutical Co. Ltd is a public share holding company 
engaged in the manufacture and sale of bulk drugs .Hisun is a well-known in the area of API 
exports. The company is principally focused in providing drugs used in anti neoplastics, 
cardiovascular treatment, anti-infection, anti-parasite, endocrine control, immune inhibitors 
and also anti-depression. It is highly active in research and development concentrating on 
chemical synthesis, microorganism fermentation, biotechnology, natural plant extraction and 
preparation development. Hisun distributes its products in domestic markets as well as in 
European and the US markets and it operates with its seven wholly owned subsidiaries. (Nexis 
UK, 2012).  
In the last 5 years ,in  domestic market Hisun has filed for  40 generic drugs of which 26 are 
approved. Which translates into a approval rate of 65 % or a new drug approval every two and 
a half months. It has filed 3 new drugs for clinical test of which 2 have been approved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACT SHEET:HISUN 
 
 Established: 1956 
 
 Headquarters: Tai Zhou 
 
 Locations: Beijing, Shanghai, Hangzhou 
 
 No .of AZ projects: Though AZ &Hisun 
planned to work on several projects; none 
of them were conceptualized so far. 
 
 Ownership: Public, listed in Shanghai stock 
exchange 
 
 Business Model: CMO, Eminent player in 
Generic Market 
 
 Client: Eli-Lilly, MSD, Alpharma  ,Axellia, 
Phizer  are some of its major clients 
 
 Employee count: 3,867 
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STEP 6-    CRO AUDIT 
 
A cross functional audit was conducted for the final evaluation of the 3 potential CRO'S .The 
audit was followed by a project team discussion where in all major and minor aspects of the 
audit was discussed and the final CRO was selected. 
 
 
Figure 14: Domains of Audit 
 
 
 
 
The details of audit is given in the appendix 4 
 
 
 
 
 
 
 
 
 
 
 
QA 
Technical 
Suitability 
Sourcing & 
commercial 
Regulatory 
Fianacial 
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Table 7:Audit Summary 
 
CRITERIA 
 
HISUN 
 
SUNDIA 
 
WUXIAPPTEC 
Technical 5 3 3 
QA 2 3 5 
Regulatory 5 4 3 
Sourcing/commercial 1 4 2 
Finance stability 4 5 5 
Suitability 0 4 4 
Summary score 17 23 22 
 
 
  
Though Hisun stands very strong in the area of technical and regulatory aspects by the virtue of 
its well established plant, scale up capabilities, technical expertise, good experience in the field 
of generics drug development and registration, strong RA team etc it scores the least among 
ƚŚĞ ƚŚƌĞĞ ZK ?Ɛ ŝŶ ƚŚĞ ĂƵĚŝƚ ĚƵĞ ƚŽ ŝƚƐ ǁĞĂŬ ƉĞƌĨŽƌŵĂŶĐĞ ŝŶ ƚŚĞ ĂƌĞĂƐ ŽĨ YA, 
sourcing/commercial and overall project suitability. Two major flaws were observed during the 
QA audit, but when report was sent to Hisun notifying this they did not respond with the 
appropriate Corrective and Preventive actions (CAPA) clearly portraying a lack of 
ƌĞƐƉŽŶƐŝǀĞŶĞƐƐ ?ůƐŽ,ŝƐƵŶ ?ƐďƵƐŝŶĞƐƐŵŽĚĞůŽĨ/Ŷ-house development of formulations does not 
suit AZ which is focussed on finding a pure CRO that can commit fully towards this project. 
There is a very significant concern of lack of transparency regarding Hisuns development of 
Valsartan formulation & conflict of interest as Hisun is  not ready to give up  on its in house 
manufacturing of Valsartan, clearly indicating a threat of competition in the future for AZ. These 
factors make Hisun unsuitable for the self-development project. 
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There is narrow difference in the audit scores between Sundia and WuxiApptec. During the 
audit it was found that both Sundia and WuxiApptec have good technical capabilities. Sundia 
has experience in the development of generic drugs and thereby more familiar with the 
technical knowhow. But they have resource shortage and lack in intermediate scale up 
capabilities. WuxiApptec on the other hand has a huge facility, capacity and scale up 
capabilities, but lack   experience in generics drug development and registration. 
WuxiApptec is strong in the areas of QA meeting the required AZ standards. During the Sundia 
QA audit, 3 major flaws were detected, but when notified about it they immediately responded 
with a convincing CAPA. 
WuxiApptec is financially very stable. Sundia was scored low in the financial criteria in  the KT 
analysis due to lack of appropriate information, but during the audit it was found that Sundia is 
financially very strong and stable even though it is not a listed company. 
Sundia has good links in the SFDA and a strong RA team therefore placing itself in a strong 
position in the regulatory area. WuxiApptec inspite of having a strong RA team and strong links 
with the health authorities, scores less than sundiaas it does not have experience in generic 
drug development, dossier preparation and registration in China. 
From the sourcing and commercial perspective WuxiApptec scores less than Sundia as it has 
quoted significantly high price when compared to Sundia. Also its lack of experience was 
another concern. But since WuxiApptec is a pure CRO, and possesses excellent facility, capacity 
and a strong team it was recommended that along with Sundia, Wuxi also be considered for the 
project to mitigate the risk of selecting just 1 CRO for the pilot project. 
 
Thus based on the Results of the audit and project team discussions Sundia and Wuxi are 
qualified as CRO'S for the CBM SD pilot projects 
. 
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5.1.7. SWOT ANALYSIS BASED ON THE AUDIT FINDINGS, DESK RESEARCH AND INTERVIEWS  
 
[Note: The SWOT depicts the strengths and weakness of the CRO Company and the opportunities 
& threat it poses to AZ] 
 
HISUN 
 
STRENGHTS  WEAKNESS 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASTRAZENECA 
 
OPPURTUNITIES                                                                           THREATS 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x Hisun is a leading Generic drug  manufacturer in China 
with Strong technical capability& a well established plant 
at Fu yang 
x Intermediate pilot scale  up capabilities: 20-40kg/bx 
x Possess good knowledge in broad areas of   generics 
development e.g. API suppliers, IP, etc.  
x Very good experience in  generic  development and 
registration  
x Convincing formulation development and structure plan 
in the RFP 
x Public listed company, financial risk is low 
 
x  In its CMO operations Hisun has a mature quality system in 
place,But for R&D activities as a CRO there are no dedicated 
QA resources and experience 
x Lack of transparency when dealing with AZ 
x High price quotation 
x Risk raised in  Quality audit observations 
x All key quality management procedures did not mention 
client communication and confirmation.  
x lack of interest to play a limited role of a CRO in the project 
x Limited experience of working with partners in the past 
x Absence of SOP in its RA center 
 
 
 
 Well-known brand name in the generics drugs market 
 Access to high technical& regulatory expertise in AZ BM 
project which will help reducing the lead time and increasing 
the chances of approval. 
 Interested in future business prospects, seems keen on a Joint 
venture which could save AZ the time taken to develop and 
register the formulations as AZ would gain access to Hisuns 
approved generic formulations 
 
 
 
 Providing CRO service is not their core competency, more 
interested in CMO activities, in house development of 
formulations etc. .therefore not directly catering to AZs 
need. 
 Conflicts of interest, as Hisun is undertaking in-house 
development of Valsartan formulation which could be a 
potential competitor for AZ s Valsartan formulation in the 
future. 
 Lack of transparency a matter of concern for AZ 
 Did not respond to the quality audit report with CAPA 
measures thus portraying lack of total commitment and 
responsiveness 
 Lack of preparation for audit  may suggest lack of interest  
ƚŽƉƌŽǀŝĚĞZ ?ƐĞƌǀŝĐĞƚŽ ?Ɛ generic formulation need 
 Possible Joint Venture with Pfizer could pose a threat to AZ  
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SUNDIA 
 
STRENGHTS WEAKNESS 
  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASTRAZENECA 
 OPPURTUNITY  THREAT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
x Sundia is pioneer in China in CRO division with a established 
formulation division.It operates purely as a CRO i.e; develop 
formulations and TT to Partner.  
x Has experience in the area of generics drug development and 
registration, familiarity with the technical knowhow. 
x Strong technical capability 
x Ability  to  select and evaluate API suppliers by conducting 
quality tests and assist in optimizing API manufacturing  
process 
x Convincing formulation development and structure plan in 
the RFP  
x Highly qualified, knowledgeable senior staff members 
x Good links with SFDA  
x Experienced CMC department in generic product 
development and registration.  
x The Pharmaceutical Development Service (PDS) business has 
been experiencing significant growth during the past 2-3 yrs 
x Private company but financially quite healthy 
x Limited  readily available resources to be deployed on the 
project 
x Lacks  intermediate scale up, maximum scale up 5kgs 
x Lack of  GMP compliance ,total  of 3 major flaws in the 
quality audit observations 
x Limited experience in on-site inspection and filing  compared 
to Hisun 
x No SOP available in R.A centre  
x Constant change in the management team could result in a 
leadership crisis within Sundia 
 
 
 
 
 
 
x Sundia caters to the need  of AZ as it is a pure service 
provider 
x Sundia will only manufacture 1 product for 1 market 
thus  no conflict of interests in that market 
x Sundia follows a mature pricing structure. Its quote is 
reasonable at   around $ 352K. 
x Potential to select & assess API suppliers for the BM 
project 
x Good links with SFDA  W 2 of their members have good 
connections with SFDA which could prove to be very 
effective to reduce the lead time in the registration 
process. 
x Experienced CMC department is a much need advantage 
for AZ team who do not have experience in the  
development & registration of generic drugs 
 
 
x
x Limited resource is a major threat,and there is a need to 
ensure  sufficient high quality resource allocated to AZ 
project  
x Possibility of manufacturing the same product in a 
different market 
x Increased risks of successful technical transfer as Sundia   
lacks intermediate scale up. 
x Recent change in the management team and its attitude 
may be a concern to AZ 
 
 
 
 
 
 
 
 
 
x
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 WUXIAPPTEC 
STRENGHTS WEAKNESS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       ASTRAZENECA 
  
  
  
OPPURTUNITIES THREATS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x Wuxi is a pure CRO which is in line with AZ's requirement for 
the project. 
x Strong quality system in place 
x tƵǆŝ ?ƐĂĚĚĞĚĐĂƉĂĐŝƚǇŵĂǇĞŶĂďůĞƚŽŚŽƐƚĂĚĚŝƚŝŽŶĂů
projects simultaneously. 
x Strong relationship with Health Authorities could help in the 
approval process 
x Expert staffs can bring about a smooth flow of operations 
x High level of interest and commitment is a positive sign 
 
 
x No hands on experience in generic product development, 
dossier preparation and registration in China. 
x Formulation development and structure plan less convincing 
than Hisun and Sundia. 
x GMP certified strong quality system in place 
x Large facility, Lots of equipment 
x Capability to scale up to 50kg scale 
x Wuxi has a good knowledge of development work 
x Very good brand name as a innovator drug CRO. 
x Strong relationship with Health Authorities 
x Possess  RA staff of very high level sourced from big 
pharmaceutical company 
x Local as well as overseas experts for CMC and generic drug 
development 
x The Pharmaceutical Development Service (PDS) business is 
experiencing significant growth during the past 2-3 yrs 
x Public listed company, financial risk is low 
 
x Lack of experience with generic drug development & filing is 
the biggest threat;AZ may need to invest more resource 
working very closely with them. 
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5.1.5 RISK ASSESSMENT OF SELECTED CRO- SUNDIA & WUXIAPPTEC 
 
 
Ref Potential 
Event or 
Scenario 
Risk Description  Threat 
or 
Oppor-
tunity 
Financial 
Impact 
Reputational 
Impact 
Total 
Impact 
 
Likelihood 
Risk 
Score 
Risk 
Category 
ASTRA Risk Improvement 
Plan 
1 
Sundia- good 
links with 
SFDA 
Good links with 
SFDA O H M H H 8 
Supply  
risks Accept   
2 
Sundia-
Technical 
transfer 
challenges 
Its maximum scale 
up capability is-
5kg.Scale up from 
5kg to 500kg in AZ 
Taizhu site is a 
challenge 
T VH L H VH 9 Supply  
risks Reduce 
Monitor and assess 
the reliability of 
process,prepare trail 
batch prior to 
commercial batch 
3 
Sundia- 
resource 
limitations  
Resource is a 
constraint, their 
current 
facility/headcount 
capacity is quite full 
T VH L H H 8 Supply   
risks Avoid 
ensure  sufficient high 
quality resource 
allocated to AZ project  
4 
Sundia-  
Generics 
industry 
experience 
Sundia has 
considerable 
experience in the 
field of generic drug 
development and 
registration  
O H M H VH 9 Supply 
risks     
5 Wuxi -capacity 
advantage 
Better ability to run 
more projects in 
terms of space and 
equipments 
O VH M H VH 9 Supply s 
risks Accept   
6 
Wuxi -lack of 
experience in 
Generics drug 
Industry  
Wuxi is a known 
name in the area of 
innovative drugs .It 
has no experience in 
the field of generics 
drug development 
and registration. 
T H M H VH 9 Supply  
risks Reduce 
Close monitoring and 
training 
7 
Wuxi -
Competent  
team   
Wuxi Possess local 
as well as overseas 
experts for CMC and 
generic drug 
development 
O H M H H 8 Supply  
risks Accept   
Note:1) The criteria definition for Impact (Financial and 
Reputational) & Likelihood is given in the appendix:5(a) 
         2) Abbreviation &details of the term ASTRA is given 
in appendix 5(b) 
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The Risk assessment has been performed by using the AZ Integrated Risk Management tool 
(IRM) as depicted above. The risk assessment highlights the main threats &opportunities of 
the Sundia and WuxiApptec which have been finalized for the pilot project.  
 
For the purpose of easy understanding the Opportunity and threat profile chart is depicted 
below to analyse the risks 
 
 
 
Figure 15: Threat & Opportunity profile of Sundia & WuxiApptec 
 
 
 
It can be noted that both Sundia and WuxiApptec have hight impact & very high to high 
likelihood risks. The formulation of appropriate risk improvement plan displaǇĞĚŝŶƚĂďůĞ Q ? ?
Undermines that AZ is being proactive and taking necessary measures to pacify the risks 
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5.2. MOLECULE ASSESSMENT 
 
Molecule assessment forms an important part of AZ Self Development project. It is 
necessary to choose the most suitable molecule out of hundreds of molecules that are 
available. Appropriate molecules have to be selected for development by evaluating them on 
multiple parameters for their viability in the China market. 
 
Of these 38 high potential molecules have been selected for the broad market project by 
building a database based from the latest sales statistics at county hospitals and CHC/CHSs, 
then a number of screening criteria is applied to the database such as Sales, price, 
feasibility, growth, safety profile etc and finally, a multi sourced approach is used to estimate 
future sales for each HPM. 
 
Of these 38 molecules AZ China Team has selected 15 molecules listed below for the Self 
Development project: 
 
1. Simvastatin 
2. Acarbose 
3. Valsartan 
4. Irbesartan 
5. Losartan 
6. Atorvastatin 
7. Repaglinide 
8. Benazepril 
9. Clopidogrel 
10. Perindopril 
11. Clarithromycin 
12. Itraconazole 
13. Fenofibrate 
14. Telmisartan 
15. Loratadine 
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7KHVHPROHFXOHVDUHHYDOXDWHGDJDLQVWVHYHUDOFULWHULD¶V 
 
x Commercial - This is based on forecasted China sales of the finished product in 2020.   
x Regulatory   - This is based on the number of licenses already approved in China in 
order to project the probability of regulatory approval 
x Legal/IP        - To determine if there are any IP constraints that prohibits the manufacture 
and sales of the drug in China market 
x Technical     - This evaluates the possible  process that is followed in the development of 
the drug & its feasibility at the AZ site 
 
x API source- To determine reliability of API sourcing from China market 
 
x BCS class-The classification of BCS indicate the potential risk of formulation 
development. 
 
x Other specifications ± To determine if the formulation requires any additional 
specifications or studies. 
 
x Equipment needs- To determine the feasibility of the HTXLSPHQW¶V required to carry out 
the process at the AZ site 
 
x Film coating-To determine the coating requirements for the formulation and its feasibility 
at the AZ site 
 
 
Table no.1 depicts the evaluation of the 15 molecules  
 
Note: Green indicates Low risk-5 
Amber indicates Moderate risk-3 
Red indicates High risk-1 
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Table 8: Molecule Evaluation 
Molecule/ strength(s)/ 
formulation  
Commercial 
(2020 sales) 
(million 
USD)  
Regulatory Legal/IP Technical API source BCS Class Other Equipment Needs 
Film 
Coating Total 
Score 
1.Simvastatin (20 & 
40mg tablet) 65.6 
more than 50 
licenses approved 
in China 
  Wet Granulation  Hisun (FDA 
approval) BCS Class II 
common 
granule/multiple 
stability studies 
None 
Y 
34 
  
2.Acarbose (50mg 
tablet) 60.2 
<5 licenses 
approved in China   
Direct 
Compression 
Hisun (FDA 
approval)  BCS Class III    
 A hopper design and 
drop/Centrifugal Filling   N  39 
3.Valsartan (80mg 
tablet) 54.2 
Innovator is 80mg 
capsule, hence 
possibly Class V 
generic application 
(efficacy studies)  
  
Direct 
Compression 
/Roller compaction 
Zhejiang 
Second Pharma 
BCS Class III 
- Risk 
associated 
with dosage 
form switch 
  
 A hopper design and 
drop/Centrifugal Filling - 
possible need for roller 
compaction. Possible 
requirement for capsule 
filling  
 Solvent 
coating 
solution 
based on 
India 
dossier  
33 
4.Irbesartan (75 & 
150mg tablet) 41.9 
about 18 licenses 
approved in China   Wet Granulation  
Huahai.  
Hisun(is 
applying for 
FDA approval) 
BCS Class II 
common 
granule/multiple 
stability studies 
 None  
 Y  
39 
  
5.Losartan (50 & 100mg 
tablets) 24.3 
<10 licenses 
approved in China   Wet Granulation  Huahai BCS Class III 
common 
granule/multiple 
stability studies 
 None  
 Solvent 
coating 
solution 
based on 
India 
dossier  
35 
6.Atorvastatin (10 & 
20mg tablets) 22 
<5 licenses 
approved in China   Wet Granulation  
Hisun (FDA 
approval) BCS Class II 
common 
granule/multiple 
stability studies 
 None  
 Y  
34 
  
7.Repaglinide (1 & 2mg 
tablets) 13.7 
<5 licenses 
approved in China   Spray Granulation  
Hainan 
Venturepharm(
Many potential 
suppliers don't 
have the API 
sales now) 
BCS Class II 
common 
granule/multiple 
stability studies 
 Top spray granulation 
system  
 Y  
29 
  
8.Benazepril (10mg 
tablet) 10.7 
<10 licenses 
approved in China   Wet Granulation  
Haimen 
Wisdom(EDMF 
as the 
Veterinary drug 
, and is 
preparing the 
DMF ) and 
Fujian Huitian 
 BCS Class II     None   Y  39 
9.Clopidogrel (75mg 
tablet) 5.4 
<5 licenses 
approved in China   
Direct 
Compression 
/Roller compaction 
Apeloa, 
Charioteer,  etc  BCS Class II    
Hopper design and 
drop/Centrifugal Filling - 
possible need for roller 
 Y  33 
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compaction  
10.Perindopril (4mg 
tablet) 5 
<5 licenses 
approved in China 
FDA warning on 
birth defect - 
please confirm 
with PS 
  
Direct 
Compression 
Two registered 
API suppliers 
don't sell the 
API now 
 BCS Class III     Hopper design and drop/Centrifugal Filling  
 Branded 
coversyl is 
f/c, some 
generics 
not  
29 
11.Clarithromycin (125, 
250 & 500mg tablets) 4.5 
no originator for 
125mg strength; 
about 90 licenses 
approved for both 
capsules &talbets 
in China 
  Wet Granulation  
Zhejiang 
Yongning, 
Zhejiang 
nexchem ˄
Japanese DMF 
and 
JapaneseFDA 
approval)  etc 
 BCS Class II  
 common 
granule/multiple 
stability studies  
 None  
 Y  
35 
  
  
12.Itraconazole (100mg 
tablet) 4.1 
<10 licenses 
approved in China   
Current UK market  
products are 
multiple unit 
pelletised systems 
filled into capsules* 
Shandong 
Fukang(FDA 
approval API)  
 BCS Class II    
 Fluidised bed coating 
system required 
alongside capsule filling  
 Capsule  31 
13.Fenofibrate (100mg 
capsule) 3.9 
about 80 licenses 
approved in China   
Wet Granulation, 
BUT, encapsulated 
formulation, 
therefore require 
capsule filling 
machines 
Zhejiang 
Nexchem, etc  BCS Class II     Capsule filling required   Capsule   27 
14.Telmisartan (20, 40 
& 80mg tablet) 3.7 
about 60 licenses 
approved in China   
Spray drying 
followed by roller 
compaction - Solid 
dispersion 
(complex 
formulation) - No 
plans to establish 
capability at 
Taizhou* 
Apeloaetc, 
Hisun is doing 
registration 
BCS Class II 
 common 
granule/multiple 
stability studies  
Top spray granulation 
system 
N 
25 
  
  
15.Loratadine (10mg 
tablet) 0.7 
originator is 
Deloratadine 5mg 
tablets. 
 about 30 licenses 
approved in China 
  
Direct 
Compression 
Hainan 
Venturepharmet
c 
 BCS Class II    
 Appropriate hopper 
design and 
drop/Centrifugal Filling  
 N  31 
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Molecules 1 to 4 are categorised in green due to their high forecasted sales value of 65.6 to 
41.9 million USD. Among these Simvastatin &Acarbose shows significantly higher forecasted 
sales of 65.6 & 60.2 million USD respectively. Molecules 5 to 8 display a moderate forecasted 
sales value of 24.3 to 10.7 million USD. Molecules 9 to 15 show relatively lower forecasted 
sales value of 5.4 to 0.7 million USD. 
 
Molecules 2, 4, 5,6,7,8,9,12 have low regulatory risks with lesser number of approved 
applications in China. Molecules 1, 3, 10, 11,13,14,15 are represented in amber as they pose 
considerable amount of regulatory risks. The regulatory issue with Valsartan 80mg tablet is 
that the dosage form of innovator drug is a capsule .Perindopril has concerns regarding 
safety. In the case of molecules 1,11,14,15 a significant number of applications have already 
been filed in China, therefore the possibility of getting regulatory approval is low. 
 
The formulations have low Legal & IP risks. However Simvastatin and Atorvastatin do not 
hold complete clarity on IP issues. 
 
Molecules1, 4, 5, 6,8,11 have low technical risks. The process followed here is wet 
granulation which is feasible in AZ Taizhou site. Molecules 2, 3,7,9,10,15 have moderate 
technical risks. They require processes such as direct compression, roller compression, 
spray granulation which is not feasible in AZ Taizhou site under current conditions. 
Molecules 12, 13, 14 pose high technical risks as they require processes are not within the 
scope of the project. 
 
Molecules 1,2,6,11,12 have low API sourcing risk; all of their potential API suppliers have 
FDA approval. Molecules 3, 4,5,8,9,13,14,15 have moderate API sourcing risk. There are 
some issues pertaining approval processes, conflicts of interest etc. Molecules 7,10 pose 
high API sourcing risks as there is a scarcity of API supply in China market 
 
All the 15 molecules belong to BCS class II (Low solubility, high permeability) or III (high 
solubility, low permeability) which is of moderate risk. 
 
Molecules 1, 4, 5,6,7,11,14 require common granule/multiple stability studies and hence are 
displayed in Amber. The rest of the molecules require no additional specifications 
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Molecules 1,4,5,6,8,11 pose low equipment risks. The required equipments are available at 
the AZ Taizhou site. Molecules 2,3,9,10,15 are represented in Amber as certain equipments 
required are not available at the new site and would need additional investment by AZ to 
obtain them. Molecules 7, 12, 13, 14 have equipment requirements that are not within the 
scope of the project and thus highlighted in red. 
 
Molecules 3 & 5 are represented in amber as they need solvent coating which is not feasible 
at AZ Taizhou site. The remaining molecules possess low risk in the coating criteria 
 
The overall scores of Itraconazole,Fenofibrate&Telmisartan are highlightedin red due to high 
risk involved in formulation process. Thus it is suggested by the China team to drop these 
molecules off the Self Development project. 
 
Acarbose, Irbesartan and Benazepril score the highest (39) and are considered most feasible 
for the project. However Acarbose and Irbesartan have high forecasted sales value of 60.2 
and 41.9 million USD respectively which is significantly higher than Benazepril which has a 
market value of 10.7 million USD. Therefore Acarbose and Irbesartan are finalized for the 
pilot project 
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5.3. PROJECT RISK ASSESSMENT 
 
As discussed in the literature, Risk assessment is a very important part of project 
management .In AZ self-development project there exist multiple types and magnitude of 
risks and it is very important for the project team to identify, study and minimize these risks 
well in advance. That way AZ can be better prepared to mitigate the risk outcomes. 
 
 
The project team has identified and listed important project risks. Once the level of impact 
(financial / reputational / others) is analysed, approach towards the risk is decided & then 
risk improvement plan or mitigation plan has been devised accordingly. 
 
 
These risks have been classified into different categories: 
 
 Regulatory risk 
 Commercial Risk 
 Technical Risk 
 
 
 
Note: Since supplier risks and molecule risk has been dealt with in the previous sections it will 
not be considered in this section. 
 
 
Table no.1 represents the risk evaluation of the AZ Self -Development project 
 
Note: The criteria for measuring the risk impact (both financial and reputational) and risk 
likelihood ĂŶĚĚĞƚĂŝůƐŽĨ “^dZ ? is given in appendix 5 
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Table 9: Project risk evaluation 
Ref Potential Event 
or Scenario 
Risk Description Threat 
or 
Oppor-
tunity 
Finan
cial 
Impac
t 
Reputati
onal 
Impact 
Total 
Impact 
 
Likeli
hood 
Risk 
Score 
Risk 
Category 
ASTRA Risk Improvement Plan 
1 Low approval 
risk 
Class 6 generic approval rate is less 
than 25%, and may be lower by the 
time AZ start filing CTP submissions 
in 2016+ 
T VH M H VH 9 Regulatory 
risk Reduce 
1) Investigate who is submitting and 
reasons for success/ failure. 
2) Leverage window of opportunity to 
speak with new Taizhou SFDA office 
to understand ways to enhance AZ 
generic filing success rate. 
3) Find shinning points or 
differentiating points in formulations. 
2 IP risk 
Global or China specific formulation 
IP constrains OSD development, 
delaying project or increasing BE risk 
for more divergent formulation 
T VH M H H 8 Commercial 
risk  Reduce 
Use Global and local IP to clarify 
development space  
 
3 BE study failure 
risk 
Bioequivalence study can only be 
started after development, tech 
transfer and at least 6 commercial 
batches, thus its failure would indicate 
a significant loss to the business. 
T VH M H H 8  Regulatory Reduce 
For formulations  presenting higher 
risk of BE failure, consider 
(1) ex-China PK, I.e.; perform  
preliminary BE study outside of China 
and examine the results  
(2) IVIVC studies i.e.; conduct In- vitro 
lab studies to preconfirm results   to 
derisk investment in TT etc. 
4 
Human 
Resource/Expert
ise Gap 
Human Resource/expertise gap in the 
area of generics drug development 
delays start of pilot/main project 
development. 
T VH M H VH 9 
Technical/H
uman 
resource 
risk 
Transfer 
Use  CRO where appropriate but 
exploit other approaches (CMO/JV) 
for difficult technical development 
and/or equipment specific OSDs 
5 
Equipment 
constrains in the 
Taizhou site 
Equipment capability and capacity 
constrains range and rate at which 
OSDs can be established in Taizhou 
T H L M VH 8 
Technical/e
quipment 
risk 
Reduce 
 when there is a need for greater 
capacity in line one activity (self-
development project) minimize the 
line 2 activities ( manufacture of 
existing AZ drugs) in the new site 
6 Formulation design 
 Lack of clarity in setting approach for 
tablet size, shape.  T L VL L H 6 
Technical 
risk Reduce 
Need to be clarified in the beginning 
by marketing colleague 
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Figure 16: Opportunity Threat Profile 
 
 
 
It can be noted that event 1-5 are medium to high impact and very high to high likelihood 
risks, falling in the red zone of the threat section indicating a high threat. The approach 
towards event 1, 2,3,5,6 is to reduce the overall impact and likelihood of risks. Thus 
accordingly risk improvement plan is formulated for each of them as depicted in the table 
The approach towards event 4 is to transfer the risks to another entity that is in a better 
position to handle it. 
 
 
 
 
 
 
 
 
 
 
 
VH
H 1, 4 2, 3
M 5
L 6
VL
VH H M L VL VL L M H VH
Likelihood Likelihood
Im
pa
c
t
THREATS OPPORTUNITIES
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                                        CHAPTER 6 
                                     Discussion 
 
A typical Pharmaceutical R&D model comprises of the following activities: 
Figure 17: Pharma R&D model 
 
 
 
Let us now analyse the R &D Model& extent of outsourcing for the AZ BM Self-Development 
project 
 
 
Oppurtunity 
Analysis 
Drug 
Research 
Discovery Development Registration 
Launch/Market
ing 
A
ct
iv
it
ie
s
Molecule assessment -         
38 HPM   Selected for the AZ 
BM Project with the aid of 
external consultants;
from this 15 HPM are 
shortlisted by the china PD 
team for the Self- 
Development project
Constitutes of 4 main stages
1. Raw material sourcing          
2.Process Development            
3. Technical transfer and 
sample batch production         
4.IND stability testing                
This includes:
1. Dossier preparation   
2. Dossier submission to 
SFDA      
3. BE study
4.Submission of  BE study 
report
After the attainment of 
LML, the launch and 
marketing activities are 
soley undertaken by 
Astrazeneca
O
p
e
ra
ti
n
g
 M
o
d
e
l
Captive 
+ 
Outsourced
Captive 
+ 
Outsourced
Captive 
+ 
Outsourced
Captive
LEGEND : Most Outsourced Most Captive
Drug Research and Discovery 
- phases not applicable for Generic 
R&D model 
Not Applicable
E
x
te
n
t 
o
f 
o
u
ts
o
u
rc
in
g
Oppurtunity Analysis Drug Research Discovery Development Registration
Launch/
Marketing
Figure 18: R&D Model for AZ BM Self-Development project 
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It can be observed that there is significant extent of outsourcing involved in most of the 
phases of the AZ BM self-development project. Drug research and discovery activities which 
are usually conducted in house by original brand makers does not form a part of generics 
 R &D model since these drugs are imitations of existing drugs and therefore escapes the 
tedious research and discovery phase. The majority of the development phase is prone to 
outsourcing; raw material sourcing and process development activities are outsourced to a 
greater extent whereas Technical transfer, sample batch production and stability testing is 
jointly conducted by the CRO and AZ scientists in the AstraZeneca site. Even though most of 
the development activities are outsourced AstraZeneca reviews the progress after each and 
every stage in order to minimize risks. Registration phase activities like Dossier preparation is 
ƉĞƌĨŽƌŵĞĚďǇƚŚĞZK ?Ɛ ?ďƵƚƌĞǀŝĞǁƐƚhe dossiers and submits it to the SFDA.BE study is 
conducted by the CRO ,AZ then reviews the study findings and submits the report to the 
SFDA. Therefore it is evident that though major activities of the Self Development project is 
outsourced AZ plays an important role of monitoring, controlling, reviewing the activities 
and ultimately taking the final decision. 
 
Since most of the activities of the self-development project are outsourced it is crucial for AZ 
to select the right outsourcing partners. Moreover the key objective of AZ BM project is to 
generate good quality generic drugs in the China market. China market has been in filtered 
with numerous providers of generic drugs who have not focussed on catering to quality 
needs. The competition has purely been based on price often compromising quality. 
dŚĞƌĞĨŽƌĞ ŝƚ ŝƐ ǀĞƌǇ ŝŵƉŽƌƚĂŶƚ ĨŽƌ  ƚŽ ƐĞůĞĐƚ ZK ?Ɛ ǁŚŽ ĂƌĞ ĨƵůůǇ ĨŽĐƵƐĞĚ ŝŶ ƉƌŽǀŝĚŝŶŐ
optimum services of high standards & execute a lead role in this project as AZ  is new to the 
generics drug industry .Thus a very high emphasis is laid on Supplier evaluation and selection. 
AZ follows a very intense, tedious and structured process to thoroughly examine and select 
ƚŚĞƌŝŐŚƚƐĞƚŽĨZK ?Ɛ ?dŚĞƉƌŽĐĞƐƐ ŝƐƐŝŵŝůĂƌƚŽƚŚĞŽŶĞĚŝƐĐƵƐƐĞĚďǇdƌĞŶƚ ŝŶƚŚĞůŝƚĞƌĂƚƵƌĞ
review. 
^ĞǀĞƌĂůŝŵƉŽƌƚĂŶƚĐƌŝƚĞƌŝĂ ?ƐĂƌĞĐŽŶƐŝĚĞƌĞĚďǇŝŶƚŚĞĚĞĐŝƐŝŽŶŵĂŬŝŶŐƉƌŽĐĞƐƐ ? 
KƚŚĞƌƚŚĂŶƚƌĂĚŝƚŝŽŶĂůĐƌŝƚĞƌŝĂ ?ƐůŝŬĞĐŽƐƚ ?ƋƵĂůŝƚǇ ?ƐĞƌǀŝĐĞ ?ĚĞůŝǀĞƌǇŵĂŶǇŽƚŚĞƌĐƌŝƚĞƌŝĂ ?ƐĂƌĞ
considered by AZ with the aim of developing long supplier relationship such as quality 
management practices, financial stability, technology and innovativess level &suppliers co-
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ĚĞƐŝŐŶ ĐĂƉĂďŝůŝƚŝĞƐ ? ŚĂƐ ŐŝǀĞŶ ƚŚĞ ZK ?Ɛ ŵĂũŽƌ ƌŽůĞ ǁŝƚŚ ƌĞŐĂƌĚ ƚŽ ƉƌŽĐĞƐƐ ĚĞƐŝŐŶ ?
development and engineering. There are many benefits of involving suppliers at the 
product/process design and development stages such as fast project development times, 
lower development and product cost, development of alternative solutions, selection of best 
components/raw materials and technologies, increased level of motivation, increased 
supplier originated innovation and better product quality. (Monczka et al. 1994; Burt and 
Soukup 1985;Araz et al.,2006). 
Studies show that in developing countries it is necessary to focus on product reliability and 
ƐƵƉƉůŝĞƌ ?Ɛ capacity in both technical and product aspects (Thanaraksakul ,w ., et al;2009) . AZ 
has given high importance to these factors during the selection process. 
In a research work on generic pharmaceutical firm it was found that regulatory compliance  
is the most favoured criteria  as there is  increased pressure from the  Government and the 
FDA to comply with the rules and regulations governing the quality of  products and 
processes etc ( Enyinda et al 2010 ). In the CRO selection process for AZ BMSD project 
regulatory criteria is given very high importance (25% weight age). 
Along with the hard factors like price, quality, delivery, services AZ also gives significance to 
soft, difficult to quantify factors such as strategic direction, management compatibility, and 
strategic commitment to buyer etc during the screening process. 
 
6.1 Insights on the findings of KT analysis: 
Capability vs. Cost Advantage: As noted earlier in the analysis section Hisun, despite of 
ŚĂǀŝŶŐ ƚŚĞ ůĞĂƐƚ ĐŽƐƚ ĂĚǀĂŶƚĂŐĞ ĂŵŽŶŐ ƚŚĞ  ? ZK ?Ɛhas been ranked 1stin the overall KT 
analysis due to its significantly high score in the capabilities area. Hisun is a known player in 
the generics drug market, but being a CRO is neither their core competency nor their 
preferred business model, thus they have quoted a high pricing structure to provide this 
service. 
Sundia has the highest cost advantage and a small difference in capabilities compared to 
WuxiApptec whose cost advantage is significantly low thereby placing Sundia in the 2nd 
position.. According to a senior member in the AZ China PD team this difference in the 
pricing reflects on the attitude of CRO. Sundia has adopted a more mature pricing policy. 
Sundia has a good customer base in the domestic generic market, they have a good clarity 
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on the project, and they are willing to take more risks as they are more confident about the 
process. WuxiApptec on the other hand even though has very good knowledge and skills 
they are relatively new to this market, they do not have an exact estimate on the 
requirements of the project. Thus they may quote a higher price to reduce the risks of 
venturing into a new arena.  
Novast was eliminated at the end of KT analysis on the account of a score less than 50% and 
its unwillingness to provide all the required facts and figures to AZ. Information sharing 
ǁŚŝĐŚŚĂƐďĞĞŶŚŝŐŚůŝŐŚƚĞĚĂƐŽŶĞŽĨƚŚĞĐƌŝƚĞƌŝĂ ?ƐĨŽƌƐƵƉƉůŝĞƌƐĞůĞĐƚŝŽŶŝŶƚŚĞůŝƚĞƌĂƚƵƌĞǁĂƐ
not fulfilled by Novast. 
 
Literature opines that though Kepner-Tragoe (KT analysis) is an industry recognized vendor 
selection aid, Analytical Hierarchy Process (AHP), is a viable decision support technique that 
has gained even deeper support in the academic as well business communities. 
It is recognized as being a consistent, structured, and repeatable methodology that is critical 
to choosing external service providers. (Chronis,T,200 ). As discussed in the literature AHP 
ŽĨĨĞƌƐ Ă ŵĞƚŚŽĚŽůŽŐǇ ƚŽ ƌĂŶŬ ĂůƚĞƌŶĂƚŝǀĞ ĐŽƵƌƐĞƐ ŽĨ ĂĐƚŝŽŶ ďĂƐĞĚ ŽŶ ƚŚĞ ĚĞĐŝƐŝŽŶ ŵĂŬĞƌ ?Ɛ
judgments concerning the importance of the criteria and the extent to which they are met 
by each alternative. For this reason, AHP is ideally suited for the supplier selection (Tahriri, 
2008). So it is suggested that AZ could consider the AHP tool for supplier evaluation as it is 
more precise and reliable than KT analysis. 
 
6.2 Insights on Audit findings: 
The final step followed by AZ BM SD team in the CRO evaluation process is a cross functional 
audit. According to the literature given the performance demands placed on suppliers and 
the high cost of switching suppliers, the use of site visits to evaluate supplier capabilities is 
an essential part of the selection process. While the level of commitment, cost, cross 
functional support of making site visits are high, the cost of making a poor selection decision 
is even higher. (Trent) 
An interesting point to note is that Hisun who scored the highest in KTanalysis was 
eliminated out of the project after the audit. KT analysis was conducted solely based on the 
information given in the RFP. But when the team actually paid a formal visit to the site they 
found that many important factors that were not noticed prior to this was now obvious. 
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Especially the soft suitability factors like management compatibility, strategic direction, 
commitment, responsiveness & transparency was lacking in Hisun. 
Research work indicates that non-quantifiable factors have a greater impact on performance 
than hard, more quantifiable criteria (Kannan,V et al). In fact problems related to hard 
factors like quality, delivery etc can be managed better when there are shared expectations 
and objections. From the analysis section of this report it can be seen that Hisun despite of 
being strong in hard factors like regulatory, technical aspects was found unsuitable for the 
project due these soft factors. As the CRO has a vital role to play in this project the soft 
factors cannot be ignored. There prevails a matter of conflict of interest regarding Hisuns in 
house development of formulations which could very well be a potential threat in form of 
competition for AZ ŝŶ ĨƵƚƵƌĞ ? dŚĞ /W ŝƐƐƵĞ ŝƐ Ă ǀĞƌǇ ďŝŐ ĐŽŶĐĞƌŶ ĂƐ ƚŚĞƌĞ ŝƐ ƌŝƐŬƐ ŽĨ  ?Ɛ
technical know being used in Hisuns in house formulation. Such factors cannot be monitored 
well. Also the success of any project is highly dependent on the expertise and knowledge of 
the staff members. According to the project leader during the audit and interactions it was 
ĨŽƵŶĚ ƚŚĂƚ ,ŝƐƵŶ ?Ɛ ƚĞĂŵ ǁĂƐ ŶŽƚ ǁĞůů ǀĞƌƐĞĚ ŝŶ ƚŚĞ ZK ĂĐƚŝǀŝƚŝĞƐ ĂƐ ŝƚ ŝƐ ŶŽƚ ƚŚĞŝƌ ĐŽƌĞ
competency .Moreover Hisun has clearly displayed an interest in a joint venture with AZ 
rather than being limited to CRO activities which at that point of time was not preferred by 
AZ displaying management incompatibility. Thus the mentioned weaknesses of Hisun 
overshadow its strengths and rules out the feasibility of it being finalised for the BM project. 
KŶ ƚŚĞ ĂĐĐŽƵŶƚ ŽĨ ^ƵŶĚŝĂ ?Ɛ ĂŶĚ tƵǆŝƉƉƚĞĐ ?Ɛ ƉĞƌĨŽƌŵĂŶĐĞ ŝŶ ƚŚĞ ĂƵĚŝƚ ĂƐ ƉĞƌ 
expectations, both have been selected for the pilot project as elaborated in the analysis 
section. 
 
6.3 Supply strategy: 
The supply strategy framework which has been elaborated in the Literature review will be 
applied to the AZ BM self-development project to analyze the supply market and develop 
purchasing strategies. 
 
6.3.1. Supply positioning 
The supply-positioning tool helps to segment the AZ BM self-development project sourcing.  
 “y ? ĂǆŝƐ ƌĞƉƌĞƐĞŶƚƐ ƚŚĞ ƌĞůĂƚŝǀĞ ǀĂůƵĞ ŽĨ ƚŚĞ ŝƚĞŵ ?ƐĞƌǀŝĐĞ ĂŶĚ ƚŚĞ  “z ? ĂǆŝƐ ƌĞƉƌĞƐĞŶƚƐ
exposure or potential risk and business impact.   
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Strategic Security 
 
Strategic Critical 
 
Tactical Acquisition 
 
Tactical Profit 
 In 2020, the forecasted sales of 15 OSD molecules will be 319.9m USD rendering relative 
value of item/service as high.  
The exposure or risk will be very high because the generics drugs sourcing requires reliable 
source of supply, high standards of quality, regulatory approvals, SHE compliance.  
So based on the Supply Positioning grid, the generics drug sourcing can be positioned as 
 “Strategic Critical ? ? 
 
 
 
 High 
 
Risk/exposure 
 
 Low 
 Low High 
 Cost/Value 
As the name implies Strategic Critical is critical to the overall profitability, competitiveness 
and wellbeing of the buying organization.The Purchasing Goal for Strategic Critical is to 
manage supply. This category will require the highest level of buying skills. Buyer will have 
to keep in very close touch with the supply market and monitor vendor dependencies. 
It will have to spend ample effort in managing existing suppliers to ensure that they are 
capable of meeting the demands (Technical, quality, regulatory etc)   currently and in the 
future. This is the area where partnership concept could most effectively be used. All the 
items will need to be kept under continuous review to ensure that suppliers can continue to 
supply and that prices are kept within reasonable bounds 
 
Action Scenario by AZ: 
Supplier Analysis: AZ has followed a tedious and structured methodology to evaluate and 
select suppliers. In depth analysis like KT analysis, cross functional audits and discussions 
have been conducted prior to final selection of the CRO. 
Length of contract: A long term contract is desired by AZ, but this is purely based on the 
success of the pilot project. 
Figure 19:Supply Positioning 
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Supplier relationship: As AZ is new to the field of developing generic drugs it relies on the 
CRO to take the lead role. A collaborative relationship is desired.  
Price management: Milestone payment methodology is followed i.e., after each successful 
completion of each stage of the project payment is done. However a down payment of 20% 
is done in case of either success or failure of the project. 
Contract: It will be a detailed commercial framework including technical, financial, quality, 
regulatory etc requirements  
The overall emphasis in this Strategic critical area will be to assist competitiveness. This is 
much wider than just price advantage and would include rapid innovation, earlier time to 
market and superior product quality. 
 
6.3.2. Supplier Preferencing Matrix: 
 
As discussed in the literature review the Supplier Preferencing framework (Figure 8) allows a 
company to consider how their suppliers view them. 
 
 
 
 
  
 
 
 
 
 
.  
  
 
 
 
 
 
Note- ŽƌĞ ?tƵǆŝƉƉƚĞĐ ?^ƵŶĚŝĂ ?ƐǀŝĞǁŽĨ 
           Develop ?,ŝƐƵŶ ?ƐǀŝĞǁŽĨ 
 
Since both WuxiApptec &Sundia are pure service providers (CRO) the value of business is 
certainly high and as AZ is a well-established brand name and a global player the 
attractiveness of the account is unquestionable. Therefore it would be justifiable to assume 
that they would consider AZ as their Core clients. Here the supplier may be expected to 
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Nurture client 
Expand business 
Seek new opportunities 
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High responsiveness 
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Give low attention 
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Figure 20: Supplier Preferencing 
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provide their customers with an optimum level of service and attention and makes every 
effort to ensure business is retained while seeking to increase profitability in a low profile 
manner. Such a supplier is very likely to be open to suggestions of strategic alliances and 
other ways of locking into the customer. (cips). 
Hisun whose business model is different from WuxiApptec &Sundia gives more emphasis to 
ŝŶŚŽƵƐĞĚĞǀĞůŽƉŵĞŶƚŽĨW/ĂŶĚĨŽƌŵƵůĂƚŝŽŶƐ ?dŚĞǇĂƌĞŶŽƚǀĞƌǇŬĞĞŶŽŶĐĂƚĞƌŝŶŐƚŽ ?Ɛ
ŐĞŶĞƌŝĐĚƌƵŐĚĞǀĞůŽƉŵĞŶƚŶĞĞĚ  ?dŚĞǀĂůƵĞŽĨ  ?ƐŽĨĨĞƌĞĚďƵƐŝŶĞƐƐ ŝƐŶŽƚŽĨǀĞƌǇŚŝŐŚƚŽ
Hisun. Nevertheless they view AZ as an attractive customer. Thus they consider AZ as 
 ?ĞǀĞůŽƉ ? ĐůŝĞŶƚƐ. Here the supplier may be expected to work hard in the short term to 
meet and exceed the requirements of the customer in order to win more business.(cips) 
dŚƵƐƌĞĂƐŽŶǁŚǇ,ŝƐƵŶ ?ƐǁŝůůŝŶŐƚŽƉĂƌƚŝĐŝƉĂƚĞŝŶƚŚĞZ&Wand host the visits is to develop the 
relationship and explore future business.  
 
 
6.3.3. Market management matrix 
 
The Market Management Matrix combines the Supply Positioning and Supplier Preference 
models to deduce whether the appropriate supplier has been selected for the particular 
business and what synergies or otherwise might exist. (cips). 
 
Figure 21: Market Management Matrix 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  dŚŝƐ ƐŚŽǁƐ ƚŚĂƚ  ?Ɛ ƐƵƉƉlier positioning (Strategic critical) and the perceived view of 
WuxiApptec &Sundia (Core) are perfectly aligned. In the case where the supplier sees this 
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business as core it may be considered a good buyer seller match which should be 
developed and encouraged This is the situation in which partnerships and strategic 
alliances are most likely to flourish (cips).  
 
,ŝƐƵŶ ?ƐƉĞƌĐĞŝǀĞĚǀŝĞǁŽĨďƵƐŝŶĞƐƐǁŝƚŚ  ?ĞǀĞůŽƉŵĞŶƚ ) ŝƐĐŽŵƉĂƚŝďůĞǁŝƚŚ ?ƐƐƵƉƉůŝĞƌ
positioning model but not to the extent of Wuxi and SundiĂ ?Ɛ ? 
When the business is in the development category for the supplier the buyer should work 
more closely with the supplier to increase the extent and content of the business. This might 
very well involve seeking out other categories of Business in which both may have a similar 
interest. 
Hisun was seeking a joint venture with AZ, working as a pure CRO for the AZ BM project was 
not very valuable for Hisun. Hisun had already obtained license for over 26 generic products 
and it was keen on handing over their rights to a multinational company to conduct 
marketing and sales activities since it is poor in this area. The profit was to be shared 
between the companies. This would ideally be a win- win situation for both companies as AZ 
would instantly obtain rights over Hisuns Drugs thereby saving on time, money and efforts to 
develop and register the drugs and Hisun on the other hand can exploit the marketing and 
sales potential of one of the top pharmaceutical brands in the world. But at that point of 
time AZ was not open to the idea of joint venture .Thus as AZ was not willing to expand the 
business, Hisun showed lack of further interest and combined with the other factors like 
conflict of interest, lack of transparency, joint venture with Pfizer etc. resulted in Hisun being 
ruled out from  the pilot project.  
 
 
6.4. Risk Assessment 
Another important aspect of this report deals with risk assessment of various aspects of the 
project. Supply risk, molecule risk and overall project risks are analysed based on the input 
provided by the project team in the analysis section of the report. Integrated Risk 
Management tool is used by AZ to carry out risk assessment. The key steps of Planning ,risk 
identification, risk analysis, Response to risks & risk mitigation plan discussed in the 
literature review has been followed by AZ for the Self-Development project. The AZ 
integrated risk management tool provides for identification of both opportunities and 
threats in a project as suggested in the literature review. Checklists are used to identify risks 
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in the Self Development project. Literature describes both quantitative and qualitative 
approaches to analysing risks. Quantitative approach relies on statistical calculations to 
determine analyse risks. According to Ahmed,A;(2007)Quantitative data is not always 
available when needed or not in the form required hence a qualitative approach using 
subjective assessment techniques are often most appropriate for risk management.AZ  uses 
qualitative approach to analyze risks. The matrix based decision model i.e; probability and 
impact grid discussed in the literature review is followed by AZ to analyze risks. Here risk is 
analysed using two parameters; Risk likelihood/probability & Risk Impact/consequence. The 
likelihood and impact are categorised as Very High, High, Medium, low and very low as 
depicted in the appendix. These criteria are predetermined and can be customised according 
to the requirements of the project by the project team members. Impact is measured in 
terms of both financial impact or time scale and reputational impact. 
Once the likelihood and impact is estimated the integrated tool automatically calculates the 
risk score or magnitude. After all the risks have been listed accordingly opportunity & threat 
profiling is performed by the integrated risk management tool as shown in the analysis 
section. The use of colours i.e. red, yellow, green for high, medium and low impact and 
probability risks in the integrated tool provides for the easy identification and understanding 
.After the risks have been analysed the response to risks is planned. The term ASTRA in this 
context is an abbreviation summarizing the main risk management options available. That is; 
 A-Avoid risk 
 S-Substitute risk 
 T-Transfer risk 
 R-Reduce risk 
 A-Accept risk. 
This mechanism of risk response is similar to that discussed in the literature review. 
 Risk Improvement plan is then proposed to either (a) better understand the nature of the 
risk or (b)to change the nature of the impact or likelihood of the risk by applying one or 
more of the ASTRA risk management options. 
 According to Ahmed,A (2007) reactive approach or a feedback approach refers to risk 
mitigation actions initiated after risk events eventuate and can be seen as initiation of 
contingency plans. On the other hand, a pro-active approach or a feed forward approach 
refers to actions initiated based on chance of a risk event occurring.AZ has adopted a 
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proactive approach and has devised appropriate risk improvement plans based on a chance 
of a risk event occurring in its Self-Development project. 
All together the integrated risk management tool used by AZ is highly simplified, user 
friendly, illustrative, flexible and captures most requisites described in the literature for 
project risk management. 
 
6.4.1 .Risk Factors 
Every project that a company undertakes is prone to some or the other risks. But there are 
certain factors that expose projects to higher than normal risk. 
Kleim, R ;( 1998) highlights several such factors which are discussed below; these factors are 
then applied to AZ Self- Development project 
 
Team size: When the team size is large, the probability of occurrence of problem is higher. 
dŚĞƌĞĂƌŝƐĞĐŚĂůůĞŶŐĞƐŝŶĐŽŵŵƵŶŝĐĂƚŝŽŶĂƐƚŚĞŶƵŵďĞƌŽĨƉĂƌƚŝĐŝƉĂŶƚ ?ƐŝŶĐƌĞĂƐĞƐ ?ůĂƐŚĞƐŝŶ
ideas, opinions, and perceptions can instigate real time problems. The number of 
interactions among people increases and thus they require greater coordination. According 
to author Stephen Robbins, when teams have more than 10-12 people, the team finds 
constructive interaction difficult. Teamwork principles of mutual accountability and 
cohesiveness that are necessary to achieve high performance become difficult in large 
teams. His advice to managers is to keep the team size to under a dozen (Robin,S;2010). 
However In a cross functional project team, the size of the team is dictated by the functions 
that have to be represented. So the team size varies by task. 
 
 
 
 
 
 
 
 
 
 
History: New projects carry more risks as the processes have not been refined. When a 
project of a similar nature has been performed in the past the likelihood of success is high. 
 
 
AZ BM Self-Development project consists of a cross functional project team .i.e.; Project 
Leader, Pharmaceutical Development team (7 members), Regulatory Team (3 members), 
Procurement Team (1 member). Business Development team (1 member), Finance team (1 
member) &Legal team (1 member).According to the project leader team of this size is 
required to carry out the multiple tasks involved in this project. 
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 Staff expertise and experience: If the staff members do not have hands on experience and 
knowledge of the subject people will struggle to learn as they go along with the project, thus 
increasing the lead time and possibility of making errors. 
 
 
 
 
 
 
 
 
Complexity: When the project is complex & sophisticated the chance of committing errors 
or slipups is quite high. New untested technologies, new processes etc. are prone to greater 
risks. 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
The Development and registration of Generics drugs is totally new to AZ which has                       
always been a dominant player in the Innovator drug industry. Therefore the risks 
associated are high due to the lack of past experience. 
 
When compared to high complexity involved in developing a new chemical entity which 
undergoes tedious phases of drug research, discovery, development, preclinical studies & 
phase0, 1, 2, 3 of clinical trials the complexity involved in the development of generic 
formulations is very low.Generic drug development escapes the complex phases of drug 
research and discovery. A generic drug product is comparable to brand/reference listed drug 
product in dosage form, strength, route of administration, quality and performance 
characteristics, and intended use (CDER,2008). Thus there exists a laid set of processthat AZ 
must follow to develop them. Moreover the time required to conduct BE study which is a 
requirement for generics drug approval is of a shorter duration (6 months) and involves less 
number of subjects (around 60) when compared to the phase0, 1, 2, 3 of clinical trials which 
takes many number of years and may involve more than 3000 subjects .Therefore the 
complexity in the development of generic drugs is quite low, but since AZ is a new entrant to 
this field there exists a certain level of complexity. 
AZ staff experience and expertise does not lie in the area of development of Generic Drugs. 
The regulatory team does not possess relevant experience in registration of generics drugs in 
China. Therefore AZ will find it challenging to give steering to CRO's with regard to the Self-
Development project as the AZ team members are new to this area. 
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 Management stability: This implies unity of direction. When there is a change in the 
management there arises a possibility of change in priorities and direction. Management 
instability can result in inefficient use of resources.    
 
 
 
 
 
 
 
 
 
 
 
 
Time compression: When the schedule for executing a task is highly compressed there is an 
increased susceptibility for risk. Availability of more time means greater flexibility and scope 
to prevent or reduce the impact of risks 
 
 
 
 
 
 
Resource availability: This includes both Tangible (Financial, physical, technology) and 
Intangible (Reputation, Human, Innovation) resources (Ed Barrows; 2010). An organization 
can respond to problems in a better way when sufficient resources are available. Abundant 
resources do not assure protection from risk, but they do provide the means to respond to 
it. Example: Sufficient financial capital brings about greater ability to secure people, 
ĞƋƵŝƉŵĞŶƚ ?ƐĞƚĐ ?ǁŚĞŶƌĞƋƵŝƌĞĚ ?Kleim, R; 1998) 
 
 
 
 
According to the project leader since the company has invested a huge amount of 230 
million USD in building the new manufacturing site in Wuxi the chances of AZ management 
changing its priorities is quite low .Moreover the present pharmaceutical situation & the 
huge opportunity in the China market for generic drug industry will continue to keep the 
management interested in this area. But the recent joint venture of Pfizer and Hisun has 
ƌĂŝƐĞĚƋƵĞƐƚŝŽŶƐŽŶƚŚĞ ?ƐĐŚŽƐĞŶďƵƐŝŶĞƐƐmodel for developing generic drugs. 
The new site will be ready only by the end of 2014, so that gives AZ considerable amount to time 
to identify, analyze and evaluate various risks involved in the project and device suitable risk 
improvement plans. 
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Thus it can be seen that factors such as project history, Staff expertise and experience & 
Resource availability are some of the main concerns that might affect the successful 
execution of the AZ project if not dealt with effectively. 
 
Now that various aspects of the AstraZeneca Self-Development project has been analysed 
the report will discuss business models that are being used by various pharmaceutical 
companies to strengthen their position in the generic drug Industry. 
 
 
 
 
 
 
 
 
 
  
Since AZ is new to the generic industry it does not have all the required resources at its 
ĚŝƐƉŽƐĂů ?/ŶƚĞƌŵƐŽĨƚĂŶŐŝďůĞƌĞƐŽƵƌĐĞƐƚŚĞƌĞƐŽŵĞĐŽŶƐƚƌĂŝŶƚƐƉĞƌƚĂŝŶŝŶŐƚŽĞƋƵŝƉŵĞŶƚ ?Ɛ
&capacity but it lacks significantly in the area of intangible factors. It lacks in terms of human 
resources as they do not have members with expertise and experience in generics drug 
development and registration.AZ has a very good reputation in China in branded drug market, 
but it is a new name in the area of Generics. These Intangible resources are main sources of 
competitive advantage for an organization (Villalonga, B; 2000) .Therefore this significant gap 
ŝŶĂǀĂŝůĂďŝůŝƚǇŽĨƌĞƐŽƵƌĐĞƐĐŽŵƉƌŽŵŝƐĞƐ ?ƐĂďŝůŝƚǇƚŽĂĚĞƋƵĂƚĞůǇƌĞƐƉŽŶĚƚŽƌŝƐŬƐ ? 
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6.5. Trends in the Generic Drug Industry  
Generic companies have responded to challenges and heavy competition in the industry 
through vigorous M&A activities and partnerships rather than organic growth, driven by 
need for: 
 “ ?ĂĐŬǁĂƌĚŝŶƚĞŐƌĂƚŝŽŶŝŶƚŽĂĐƚŝǀĞƉŚĂƌŵĂĐĞƵƚŝĐĂůŝŶŐƌĞĚŝĞŶƚs manufacturing                                                       
 ?ZĂƉŝĚŐĞŽŐƌĂƉŚŝĐĞǆƉĂŶƐŝŽŶŝŶƚŽƐŵĂůůĞƌĂŶĚĞŵĞƌŐŝŶŐŵĂƌŬĞƚƐ 
 ? ŐŐƌĞƐƐŝǀĞ ƉŽƌƚĨŽůŝŽ ďƵŝůĚ-ŽƵƚƐ ŝŶ ŶŝĐŚĞ ? ƐƉĞĐŝĂůƚǇ ? ĂŶĚ ďŝŽůŽŐŝĐƐ ƉƌŽĚƵĐƚƐ ?  ?,ĂƌĚŝŶŐ ?  ?
2010) 
Figure 22 depicts the amount spent on M&A activities in the generic industry during the 
period 2000-2009; the number of deals & total spending on deals has grown over the years 
 
 
Figure 22: Generic Industry Spending on M &A activities 
 
 
 
The four major generic companies worldwide in terms of sales, Teva, Mylan, Sandoz, and 
Watson, which are responsible for nearly 50 per cent of generic prescriptions in the US, and 
nearly 40 per cent worldwide, have all used M&A to gain market share. (Harding, D, 2010) 
 
Figure shows M&A Spend distribution by tier across the top 100 generic companies during 
the period 2000 to 2009.It can be observed that since 2000, most of the M& A  investment 
have been undertaken by the top 10 players in the field. (Harding, D, 2010) 
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6.6. Comparing generic drugs development business model of AZ against 
other Big Pharma companies 
 
Generic business model adopted by some of the big pharma companies will be discussed in 
the case studies below ,then it will compared anĚĐŽŶƚƌĂƐƚĞĚĂŐĂŝŶƐƚ ?Ɛ^ĞůĨ-Development 
model to weigh the pros & cons. 
 
Case Study: 1 
A global branding giant joins a global Player in generics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Procter & Gamble Company (P&G): A well-
known leader in the creation of branding 
strategies sustained by robust product 
innovation, consumer segmentation and 
marketing practices has revamped its 
strategy in consumer health .It aims to 
reach 5 billion consumers by 2015. Most of 
the recent growth in consumer health sales 
has resulted from a good performance in 
developing countries, where the impact of 
the global recession was not very high. 
(Euromonitor,2011) 
Teva Pharmaceutical Industries Ltd: A 
global generic drugs manufacturer has 
significantly expanded its presence in 
most regions of the world through 
acquisitions and investments. During the 
period of 1995-2011 Teva has been 
involved in 21 M&A activities and has 
achieved significant growth. One of the 
most recent strategies of Teva is to 
expand in the consumer health industry 
through mature categories like 
respiratory, analgesics and digestive 
remedies. (Euromonitor,2011) 
 
Figure 23: M&A spend distribution 
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Teva's existing pipeline comprises allergy, respiratory and women's health molecules which 
matches Procter & Gamble's existing OTC range .The Joint Venture between P&G and Teva is 
a clever strategy to sustain and flourish in the highly competitive consumer health industry. 
The companies aim to create value by increasing accessibility to affordable medicines.  
 Procter & Gamble will hold 51% ownership, and Teva the remaining 49% 
(Euromonitor,2011).dŚĞ :s ǁŝůů ďƌŝŶŐ ƚŽŐĞƚŚĞƌ ĞĂĐŚ ĐŽŵƉĂŶǇ ?Ɛ ĐŽŵƉůĞŵĞŶƚĂƌǇ ĐĂƉĂďŝůŝƚŝĞƐ
and existing over-the-counter (OTC) medicines(P&G,2011).Teva has great expertise in, 
manufacturing, regulatory affairs, over 1,500 active ingredient pharmaceuticals (APIs) & a 
global presence. Procter & Gamble on the other hand brings branding know-how, marketing 
expertise and a powerful portfolio of brands.  
The global synergies will play an important role in various countries. For example, Procter & 
Gamble has strong sales in India, where Teva has a very small presence. Likewise Teva holds 
a prominent position in Russia that Procter & Gamble lacks (Euromonitor, 2011) ?dŚĞ “W'd
Healthcare, ? :ŽŝŶƚ ǀĞŶƚƵƌĞ ŝƐ ƐĂŝĚ ƚŽŚĂǀĞ ƚŚĞ ƉŽƚĞŶƚŝĂů ƚŽ ƌĞĂĐŚĚŽƵďůĞ-digit sales growth 
and $4 billion in sales towards end-of-decade. (P&G, 2011) 
 
Case Study: 2 
 
A Joint Venture between Multinational Pharmaceutical Company: Pfizer and Leading 
Chinese Pharmaceutical Company: Hisun 
Like all MNCs, Pfizer, the world largest drug maker is looking to expand into smaller Chinese 
cities and rural areas, which are now growing faster than traditional markets like Shanghai 
due to the expansion of medical insurance and other healthcare reforms. It has recently 
undergone a Joint Venture with Zhejiang HisunPharmaceuticals. This JV aims to Provide 
High-Quality and Affordable Branded Generic Medicines for Patients in China and Global 
Markets. It is one of the first JV between a multinational pharmaceutical company and a 
local leading pharmaceutical company in branded generic medicines in China , MNC's usually 
tend to acquire such companies. These are two totally different companies, one is state 
owned and the other one a big multinational.Hisun-Pfizer has a combined investment of 
$295 million and a registered capital of $250 million. Hisun holds 51 percent share and Pfizer 
holds 49 percent .Hisun-Pfizer Pharmaceuticals will develop, manufacture and commercialize 
off-patent pharmaceutical products in China and global markets.Hisun-Pfizer will exploit 
Shraddha Shetty Page 99 
 
,ŝƐƵŶ ?Ɛ ƉƌŽĚƵĐƚ ƉŽƌƚĨŽůŝŽ ? ďƌŽĂĚ ŵĂƌŬĞƚ ŽƵƚƌĞĂĐŚ ? ĂŶĚ ĐĂƉĂďŝůŝƚŝĞƐ ŝŶ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ĂŶĚ
commercialization of branded generics,dŚĞ :s ǁŝůů ĂůƐŽ ďĞŶĞĨŝƚ ĨƌŽŵ WĨŝǌĞƌ ?Ɛ ǁŽƌůĚ ĐůĂƐƐ
research and development (R&D), manufacturing ,quality management, marketing and 
operational capabilities.(Grogan,K. 2012),(Pfizer, 2012) 
 
The above two are examples of inorganic business models followed by big Pharma 
companies which has its advantages and disadvantages when compared to organic business 
model of AZ. 
When an organization adopts an inorganic growth strategy (M&A, JV, Strategic alliance) 
 time-to-market is substantially reduced which gives businesses a significant competitive 
edge ?ǆĂŵƉůĞWĨŝǌĞƌ ?Ɛ:sǁŝƚŚ,ŝƐƵŶŚĂƐŐŝǀĞŶWĨŝǌĞƌƚŚĞůŝĐĞŶƐŝŶŐƌŝŐŚƚƐŽǀĞƌ,ŝƐƵŶƐŐĞŶĞƌŝĐ
products which would otherwise take many number of years for it to develop and register 
.Also the risk of the drug not being approved by SFDA is ruled out as ,ŝƐƵŶ ?Ɛ ŐĞŶĞƌŝĐƐ
products already have LML. Thus through this JV Pfizer can enter the China broad market 
before its competitors (like AstraZeneca) and capture market share .On the contrary AZ will 
require about 4-5 years since it has to undergo the various stages of development and 
registration of the drug. Also since the approval rate for class 6 drugs (generic drug) is quite 
low in China there arises a risk of rejection. 
 
The other benefits of inorganic growth models are: 
 Instantaneously adds new brands and product or service lines to the acquiring 
company 
 Creation of synergies 
 Provides access to new customer base and helps expand to new geographical 
locations 
 Expands  assets, income and market presence 
  Many a times, an established marketing channel also becomes available 
 Economies of scale are achieved over a period of time. 
  Exposure to new management skills 
 Stronger line of recognition because of the pooled value of the two businesses 
 Provide companies with the opportunity to gain new capacity and expertise 
 Access to more resources, including expert staff and technology 
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 Sharing of risks with  venture partner 
 /ŶƚŚĞĂŐĞŽĨĚŝǀĞƌƐŝĨŝĐĂƚŝŽŶĂŶĚĐŽŶƐŽůŝĚĂƚŝŽŶ ?:s ?ƐƉĂǀĞƐĂǁĂǇĨŽƌĐŽŵƉĂŶŝĞƐƚŽĞǆŝƚ
from non-core businesses. (RP Emery & Associates , 2011) (In Focus,2009) 
 
Inorganic growth strategies pose some major risks as well, For Example in Pfizer  WHisun JV, 
WĨŝǌĞƌ ŚĂƐ ĂĐƋƵŝƌĞĚ ƌŝŐŚƚƐ ŽǀĞƌ ŵĂŶǇ ŽĨ ,ŝƐƵŶ ?Ɛ ƉƌŽĚƵĐƚƐ ? ďƵƚ ƐŝŶĐĞ ƚŚĞǇ ŚĂǀĞ ŶŽƚ ďĞĞŶ
involved in the development of these products they may not possess complete knowledge of 
the details and technicalities involved in the development and registration of these drugs. 
Moreover Hisun whose core competency does not lie in CRO activities as discussed earlier in 
the analysis section may have also outsourced the R&D process of these products to a CRO 
and therefore may themselves not have complete expertise in this area.AZ on the other 
hand having being actively involved with the CRO in the Development and Registration of 
the Generic Drugs will gain complete knowledge & will be aware of all the complexities and 
technicalities that exists in the development and registration of these drugs. They will be in a 
better position to control the quality of the drug and cater more efficiently to their goal of 
providing high quality generic drugs to the China broad market. 
Pfizer-Hisun JV is a rare partnership between a Multinational and a Local leading 
ŽƌŐĂŶŝǌĂƚŝŽŶ ?dŚŝƐǀĞŶƚƵƌĞƵŶĚŽƵďƚĞĚůǇŚŝŐŚůŝŐŚƚƐWĨŝǌĞƌ ?ƐƐƚƌŽŶŐĐŽŵŵŝƚŵĞŶƚƚŽŚŝŶĂ ?Ƶƚ
there is a big difference in the culture, practices, norms and operations of both the 
organization. This difference could eventually lead to real time problems if not handled 
efficiently. The chances of occurrence of such problems is quite low in the case study 1 
which describes the JV between two global leaders, since they both are multinational 
companies there may be similarities in their outlook, business culture and practices which 
may lead to smooth functioning of the business. 
It takes considerable time and effort to build the desired relationship. Partnering with 
another business could be challenging. Problems are inevitable if: 
 The objectives of the undertaking are not very clear, precise and communicated to 
everybody involved. 
 There is a disparity in levels of skills, expertise, investment or resources brought into the 
venture by the different partners. 
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 Different cultures and management styles could lead to poor integration and co-
operation. 
 The partners don't provide enough leadership, commitment, backing and support in the 
initial stages. 
The Success of a joint venture is highly dependent on thorough research and analysis of 
the objectives.(RP Emery & Associates , 2011) 
 
Organizations growing organically (such as AZ Self-Development project) do not measure 
their success on financial metrics alone; they take careful note of other factors like customer 
contentment, product quality, logistics and supply chain metrics etc. Some of the classic 
characteristics of companies which prefer the route of Organic Growth are: 
 Customer centricity. 
 Capacity to provide unique value propositions. 
 Building brands and marketing networks to serve consumers better. 
 Discipline and focus for Growth strategies. 
  Willingness of the management to take risks which are well planned. 
(In Focus, 2009) 
To conclude, both Organic and In Organic Growth options offer intrinsic value in their 
ownway. A good management principle would be to use a combination of both methods to 
gain a steady growth pattern in the business. (In Focus, 2009) 
 
 
 
 
 
 
 
. 
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                                     CHAPTER 7  
     CONCLUSIONS AND RECOMMENDATION 
 
The objective of this research has been to conduct a detailed analysis of the AstraZeneca 
generic drug development project by first analysing the various China Macro environmental 
factors that impact the development and Registration of these drugs, next the CRO selection 
process was to be examined and the capabilities, strengths and weakness of the shortlisted 
&52¶VZHUH WREHDVVHVVHG7KHQ WKHYDULRXV ULVNVDIIHFWLQJ WKHSURMHFWKDG WREHDQDO\VHG
and evaluated. Additionally, secondary objective was to highlight the generic drug 
GHYHORSPHQW PRGHOV RI VRPH µ%LJ SKDUPD¶ FRPSDQLHV ZKLFK ZHUH WR EH WKHQ FRPSDUHG
against the AZ business model to weigh their pros and cons. 
Once the objectives were finalised, extensive literature was reviewed to gain in-depth 
understanding of the 2 main areas of the research; Supplier selection and Project risk 
assessment. Moving on, the current scenario of the pharmaceutical industry and the generic 
market opportunities in the China market was discussed. Though the China generic market 
has great potential it is not free of obstacles. Therefore a PESTEL Analysis was performed to 
gain a thorough understanding of various positive and negative trends affecting the generics 
drug industry. The PESTEL revealed newly launched China healthcare reforms, growing 
economy, aging population, untapped rural market as the main sources for opportunities in the 
Generic market. Low approval rates, complex regulatory system, intense competition, IP 
issues and Fragmented China market pose major challenges for the development and 
registration of generic drugs.  
Mapping of Key processes of the Self-Development project shows the extent of Involvement 
of the CRO in the project. AZ being new to this field requires the CRO to play a leading role 
in the execution of this project. Starting from procurement of API until the final step of 
attainment of LML the CRO plays a very active role. Although there are multiple critical 
factors in the project, selection of the right CRO is the key critical factor to the successful 
execution of the self-development project. 
The CRO selection process followed by AZ is detailed and structured to assess CRO 
capabilities in multiple areas like regulatory, technical, financial, sourcing etc. Though 9 
suppliers operating under different business models were chosen for the Screening process, 
WKHILQDO&52¶6WKDWZHUHFKRVHQIRUWKHSLORWSURMHFWZHUHSXUHVHUYLFHSURYLGHUVDVSHUWKH
requirement of AstraZeneca. KT analysis and site Audit were the two main formal techniques 
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used to evaluate CROs. Hisun which scored the highest in the KT analysis secured the last 
position after the audit. Even though they were technically very capable it was found that 
intangible factors like incompatibility, lack of strategic commitment, conflict of interests etc. 
rendered Hisun unsuitable for the project. On the other hand although Sundia and 
WuxiApptec were lacking in some specific area (Sundia-Resource limitation, Wuxi-
inexperience in generics area) they were ultimately selected for the pilot project due to their 
RYHUDOO VXLWDELOLW\ WRZDUGV WKH SURMHFW $OVR µVRIW¶ IDFWRUV OLNH UHVSRQVLYHQHVV FRPPLWPHQW
pro activeness RIWKHVHWZRFRPSDQLHVKDYHSOD\HGDVLJQLILFDQWSDUWLQJDLQLQJ$=¶VWUXVWWR
offer the pilot project to these CROs. 
7KRXJK $=¶V VXSSOLHU selection techniques are quite comprehensive, minor improvements 
could regularly be conducted by revisiting both industry and academic sources. For example 
AHP tool (Analytical hierarchical process) could be considered in the place of KT analysis 
since AHP tool is well accepted as a more effective tool for selecting suppliers. 
Molecule assessment evaluates the 15 shortlisted molecules against various criteria and 
classifies them as high, medium or low risk. Acarbose and Irbesartan are finalized for the 
Self-development pilot project due to their high commercial value, low regulatory risks, 
technical feasibility etc. 
The supply risk assessment and project risk assessment is conducted on the AZ integrated risk 
management tool. 
Based on supply positioning technLTXH WKH JHQHULF GUXJV VRXUFLQJ LV FRQVLGHUHG µVWUDWHJLF
FULWLFDO¶GXH WR LWVKLJK ULVNDQGKLJKYDOXHFKDUDFWHULVWLF7KH6XSSOLHU3UHIHUHQFLQJPRGHO
UHYHDOVWKDW6XQGLDDQG:X[L$SSWHFFRQVLGHU$=¶VJHQHULFGUXJEXVLQHVVHVDVµcore¶ 
 and therefore will be very cooperative and accommodating. They will go an extra mile to be 
in good terms with AZ. Literature suggests that partnerships in business are very successful 
when the supplier perceives a buyer as µcore¶. Therefore if AstraZeneca intends to form 
strategic alliance or JV with the CRO, then it would be recommended to partner with a CRO 
that would consider Astra as their µcore ¶business. Hisun On the other hand FRQVLGHUV$=¶V
generic drug business as µdevelopment¶. Hisun seeks to expand its business, thus Hisun was 
interested in a JV with AZ as they want a better business prospect. 
Project risk assessment considers various risk factors like regulatory risk (approval risk, BE 
risk), commercial risk (IP risk) and technical/resource risk (human resource, equipment risk). 
Since all of these are high impact-high likelihood risk AZ team has devised a risk 
improvement plan to reduce the impact and likelihood of these risks. AZ is proactive in its 
risk management approach. Several project risk factors that have been discussed in the 
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previous chapter like resource inavailability, history, inexperienced staff and expertise holds 
true in case of this project. These are some of the concerns that might affect the successful 
execution of the project if not dealt with effectively. 
 Moving on to the secondary objectives, the current trends show that most pharma 
companies pursue inorganic growth. Case studies are used to signify the difference in trends 
within the pharma industry regarding partnering through a JV. In one case a global pharma 
signs a JV with global generics Drug manufacturer and on the hand Pfizer enters into a JV 
with Hisun which is comparatively a much smaller China specific company. When comparing 
$=¶V PRGHO WR RWKHU business models it was found that both have their advantage and 
disadvantages. The selection of an appropriate model depends on a company¶s strategy and 
vision. 
Though the AZ model is time consuming and has more regulatory obstacles, its business 
model is in line with its mission of producing high quality, low cost drugs. Moreover the time 
taken is not a big obstacle as AZ will acquire complete knowledge and complexities that 
underlie the development of generic drugs and LML processes. It could consider taking a 
short term approach of a JV or acquisitions, to acquire a presence in the China generic market 
place.  
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                                        APPENDIX 
 
Appendix 1.Steps in KT analysis 
¾ Statement of Purpose: commonly referred to as the decision statement and is a 
general overview of key objectives. The statement presents the boundaries and 
intent of the decision process.  
¾ Establish Objectives: Takes the general decision statement and identifies specific 
objectives and results that will be obtained by implementing the process.  
¾ Classify Objectives: Process of characterizing and sorting the decision criteria into 
two basic categories. 1) Criteria that must be achieved in order for the effort to 
achieve a high probability of success. These criteria are classified as MUSTS and are 
ĂďƐŽůƵƚĞǇĞƐ ?ƐĂŶĚŶŽ ?Ɛ ?&ŽƌĞǆĂŵƉůĞ ?ŝŶƚŚĞĐĂƐĞŽĨĂǀĞŚŝĐůĞƐĞůĞĐƚŝŽŶ ?ƚŚŝƐǁŽƵůĚďĞ
the engine. The inability of an alternative to meet the requirements is considered a 
fatal flaw. (2) Those that are critical to achieve a viable outcome but are accepted in 
lesser degrees. There criteria are viewed as WANTS. Using the same car example, this 
would be a comparative picture of how the alternatives compare to each other, i.e. 
leather seats in relation to cloth seats.  
¾ Weigh the WANTs: individually weighs each WANT criterion to establish priority 
among the decision factors. The factors are weighed on a scale of 1 least important & 
10 (Most critical).  
¾ Compare Alternatives: validate the objectives by testing that they satisfy objectives 
and compare them against each other.  
¾ Choose the best course of action: Final recommendation of the selected course of 
action. Included in this step is adequate due diligence in that all of the steps are 
reviewed to ensure the recommendation adequately meets the decision objectives, 
(Chronis,T,200). 
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Appendix 2: Healthcare reform blueprint through 2020 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Shraddha Shetty Page 115 
 
 
 
Appendix 3: Summary of Analysis  (Capability criteria) 
 
Hisun gets the highest score in Total weighted capability- 75% formulation sciences (22/25), 
analytical sciences (15/20), bio pharmaceutics (3/5), QA (10/15), Regulatory (18/25), project 
management  (7/10)  because of the following reasons: 
 Very good formulation development experience, well-structured development plan, 
activities and good scale up capabilities. 
 Good analytical method development experience, validation experience and capability 
and techniques 
 Low BE derisking study& equipment operating principle similar to AZ Taizhou 
 Very good response to QA questionnaire  
 Good regulatory authority inspection status 
  low on supplier quality management feedback 
 Many dedicated regulatory staff with strong background records 
 Good experience in filing and approval of generic drugs 
 Moderate challenge management in the area of formulation development an 
registration 
 Good experience dealing with onsite inspections and interactions with CDE. 
 Good project management capabilities 
 
WuxiApptec ranks second in total weighted capabilities:59%formulation sciences (15/25), 
analytical sciences (18/20), bio pharmaceutics (3/5), QA (9/15), Regulatory (9/25), project 
management  (5/10)due to the following reasons: 
 Moderate formulation development experience. 
 Well-structured  process and formulation activities. 
 Good scale up capabilities. 
 Very Good analytical method development experience, validation experience and 
capability and techniques. 
 Very good response to QA questionnaire. 
 Low regulatory authority inspection status. 
 ZĞĐĞŝǀĞĚƚŚĞďĞƐƚƐƵƉƉůŝĞƌƋƵĂůŝƚǇŵĂŶĂŐĞŵĞŶƚĨĞĞĚďĂĐŬĂŵŽŶŐƚŚĞ ?ZK ?Ɛ ? 
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 Many dedicated regulatory staff with strong background records. 
 No experience in filing and approval of generic drugs. 
 No experience dealing with onsite inspections and interactions with CDE. 
 Good project management capabilities. 
 
Sundia ranks third in total weighted capabilities: 55%formulation sciences (15/25) ,analytical 
sciences (14/20), bio pharmaceutics (3/5), QA (8/15), Regulatory (10/25) ,project 
management  (5/10)due to the following reasons: 
 Below average formulation development experience. 
 Well-structured process and formulation activities. 
 Only small scale capabilities available. 
 Satisfactory analytical method development experience, validation experience and 
capability and techniques. 
 Above average BEDerisking study, moderately similar equipment operating principles as 
AZ. 
 Very good response to QA questionnaire.  
 Low regulatory authority inspection status. 
 Below average on supplier quality management feedback. 
 2-5 dedicated regulatory staff with strong background records. 
 Limited experience in filing and approval of generic drugs. 
 Moderate challenge management in the area of formulation development and 
registration. 
 Some good experience dealing with onsite inspections and interactions with CDE. 
 Good project management capabilities. 
 
 
Novast scores the least in weighted average capability-43%formulation sciences (15/25), 
analytical sciences (10/20), bio pharmaceutics (1/5), QA (9/15), Regulatory (8/25) ,project 
management  (0/10)due to the following reasons: 
 Above average formulation development experience. 
 Well-structured process and formulation activities 
 Good scale up capabilities. 
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 Satisfactory analytical method development & validation experience, capability and 
techniques. All necessary information not provided. 
 >ŽǁĞƌŝƐŬŝŶŐƐƚƵĚǇ ?ŽƉĞƌĂƚŝŶŐƉƌŝŶĐŝƉůĞŽĨĞƋƵŝƉŵĞŶƚ ?ƐŶŽƚƐŝŵŝůĂƌĂƐ 
 Very good response to QA questionnaire. 
 Good regulatory authority inspection status, poor feedback on supplier quality 
management. 
 Good dedicated regulatory staff with strong background records. 
 No notable experience in filing and approval of generic drugs. 
 Poor challenge management in the area of formulation development and registration. 
 Poor experience dealing with onsite inspections and interactions with CDE. 
 Poor project management capabilities. 
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Appendix 4  ?Audit Summary  
 
1. Technical evaluation  
Hisun 
Advantages 
 Well established new plant 
 Strong technical capability 
 Capability to scale up to  intermediate pilot scale: 20-40kg/bx 
 Lots of experience in filings 
 
Threats/challenges/weaknesses 
 Valsartan Issue: unclear on their progress with Valsartan development. 
o Initially they mentioned that they were conducting valsartan preformulation work, 
but during the audit they did not give any clear indication about its status. 
o Also they are manufacturing Valsartan API Æ must be a reason for this activity Î 
Joint venture with Pfizer 
 Expanding business to work with major Pharma 
 Lack of preparation for audit: The VP ,R&D was only aware of the audit a day before 
 Less experience of  working with Partners in the past though currently redeveloping  
work(although JV with Pfizer) 
 Appear to be looking more for a JV, interested in manufacturing  at a commercial scale 
too, will be contractually v challenging  
 
 
SUNDIA 
Advantages 
 Operates purely as a CRO  i.e; develop formulations and TT to Partner 
 Strong technical capablility 
 Good small scale manufacturing 
 Sundia will only manufacture 1 product for 1 market thus  no conflict of interests in that 
market 
 Sundia displayed a better interest to work with Az compared to Hisun(vs. Hisun, more 
attendees at Sundia meeting including introduction from chairman) 
 Good links with SFDA  W Fred Wang used to work for them.  Feng Wang (formulation) has 
former colleagues working there 
Weakness/threats/challenge 
 Lacks in intermediate scale up, maximum scale up 5kgs 
 Minimal in-house filing experience, but recognize the shortcomings and willing to be 
trained up. 
 Possibility of manufacturing the same product in a different market 
 
WUXIAPPTECH 
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       Advantages 
 Large facility, Lots of equipment 
 Capability to scale up to 50kg scale 
 Displayed a keen interest to work with AZ (9 attendees turned up, including 5/6 VP level) 
 Willingness  to assist in strategic thoughts in terms of generating ideas to launch 
products quicker (out of box thinking) 
 Experienced regulatory CMC staff(Baxter, Lilly background)(paraphrase) 
 
 
Potential Weakness/threat/challenges 
 
 No prior experience in formulation development, no SNDA filing for generic drugs yet. 
 No regular usage of DoE, need for coaching from AZ perspective. 
 
2. Regulatory evaluation summary 
Hisun: 
Strength/advantages 
 RA colleague sourced from cross-function have strong drug development foundation.  
 Very good experience in  generic drugs development and registration  
o Well experienced in handling on-site inspections and BE study.  
o  Experienced in preparing dossier according to CTD format.  
o Possess in-depth knowledge in broad areas of   generics 
development e.g. API suppliers, IP, etc. Usually Hisun 
manufacture API in-house for their own drugs. 
 
Weakness/threats/challenges 
 Have similar thoughts of self-development on certain molecules considered by AZ 
indicating possibilities of it being a potential competitor for AZ in the future. 
 Absence of SOP in its RA center 
 Does not possess very strong relationship with Health Authorities 
 
Sundia 
Strength/advantages 
 Experienced CMC department in generic product development and registration.  
 Two of its RA staff have 1-3 years of experience in generics drug registration from a local 
company 
 Operates as a Pure CRO Company with high level drug discovery and development 
equipments.  
 One application due to be submitted for a local company this year 
 Potential to  select and evaluate API suppliers by conducting quality tests and assist in 
optimizing APi manufacturing  process 
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Weakness/threats/challenges 
 No SOP available in R.A centre  
 Does not possess a strong relationship with health authorities 
 Limited experience for on-site inspection and BE study.  
 
WuxiApptec  
  Strength  
 Possess  RA staff of very high level sourced from big pharmaceutical company 
 Local as well as overseas experts for CMC and generic drug development 
 Strong relationship with Health Authorities 
 
Threats/weakness 
 No hands on experience in generic product development, dossier preparation and 
registration in China.  
 
 Preparation of SOP under process and completion is due in june 2012 
3. Financial summary 
                                              HISUN               SUNDIA WUXIAPPTEC 
 
 
 
 
4. Sourcing and commercial summary 
 
 
Shraddha Shetty Page 121 
 
HISUN
 
 
 
 
 
 
  
Strenghts Challenges 
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SUNDAI                                                                                              WUXI 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The Pharmaceutical Development Service (PDS) business of both is experiencing 
significant growth during the past 2-3 yrs.  
Sundia/WuxiApptec arepure  service providers as desired by AZ 
Sundia currently has more 
experience of generic drug 
development and filing with SFDA, 
Wuxi has a good knowledge of 
development work and possesses a 
regulatory team with strong 
background, 
Resource is a concern, their current 
facility/headcount capacity is quite 
full, need to ensure sufficienthigh 
quality resource allocated to our 
project if choose to work with them. 
Limited experience with generic drug 
development&filing,AZ may need to 
invest more resource working very 
closely with them, need to expect 
experiencing a ««learning curve for 
the first couple of projects. 
Risk raised by QA, need for 
improvement as per AZ 
requirements, and ensure due 
arrangement in QA agreement. 
Wuxis new added capacity will enable 
AZ to host a few more projects  
Parallely. 
It wants to retain the right to 
develop the same formulation in 
other markets,need for AZ to 
evaluate and understand the impact 
of this. 
&RQVLGHULQJ6XQGLD¶V resource OLPLWDWLRQ:X[L¶VOLPLWHGH[SHULHQFH	DOVRWRPLWLJDWH
the risk of sole source, from sourcing perspective both Sundia and Wuxi are 
recommended. 
:X[L¶s quote is $603k, 
 
Sundiaquote is around $ 352K. 
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Appendix 5(a): Criteria Definition 
 
 
 
 
 
 
 
 
 
  
Measure Score Financial ($ or Time 
Delay)
Score Reputational Score
VH - Very High An event you can expect to happen VH
more than 200k USD loss 
and more than 9m project 
delay
VH
Significant global 
negative coverage 
impacting AZ business 
globally, e.g. milk 
powder scandal
VH
H - High
An event that can be 
anticipated to happen and 
this area/AZ or a closely 
allied company have 
experienced such an 
event
H 100k-200k USD loss and 6m-9m project delay H
Significant national 
(Chinese) negative 
coverage, impacting AZ 
China innovator 
business
H 
M - Medium
A rare event that can be 
envisaged but has not 
occurred in this area or in 
AZ
M 50k-100k USD loss and 3m-6m project delay M
Negative coverage 
impacting future AZ 
China Broad market 
business
M
L - Low
An event that can be 
HQYLVDJHGEXWKDVQ¶W
occurred in the company 
history (e.g. requires a 
combination of two or 
more events to occur).
L 10k-50k USD loss and 1m-3m project delay L 
Impact the relationship 
with the concerned 
CRO
L
VL - Very Low
An event that can be 
conceived but is 
considered to be very 
difficult to realise (e.g. 
requires a combination of 
several events to occur)
VL less than 10k USD loss and less than 1m project delay VL
No notable reputational 
risk VL
Financial Weighting 50 Reputational 
Weighting
50
Likelihood ImpactImpactDefinitions
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Appendix 5(b):ASTRA  
 
ASTRA' is an abbreviation summarising the main risk management options available. 
A - AVOID - A risk that is unacceptable and must to be eliminated. 
S- SUBSTITUTE - Find a less risky alternative. 
T - TRANSFER - remove the risk by making someone else accountable for its management 
through contracts or financial measures such as insurance. 
R - REDUCE - Lessen the likelihood or impact of the risk. This would include preventative and 
mitigation measures. 
A - ACCEPT - Accept the risk as being either an Opportunity worth pursuing or a threat with an 
acceptable impact and/or likelihood such that no further action is needed or possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
